Upload
others
View
5
Download
0
Embed Size (px)
Citation preview
Psoriatic arthritis: a complex
disease
– analyses on genetic and serological
biomarkers and of comorbidity
Kristina Juneblad
Department or Public Health and Clinical Medicine, Rheumatology
Umeå 2018
Responsible publisher under Swedish law: the Dean of the Medical Faculty This work is protected by the Swedish Copyright Legislation (Act 1960:729) Dissertation for PhD ISBN: 978-91-7601-910-8 ISSN: 0364-6612 New series no: 1968 Electronic version available at: http://umu.diva-portal.org/ Printed by: UmU Print Service, Umeå University Umeå, Sweden 2018 Figure 1 Reproduction, based on Fig 1 in (McGonagle and McDermott, 2006)
To my family
i
Table of Contents
Abstract ............................................................................................ iii
Abbreviations .................................................................................... v
List of papers .................................................................................. vii
Sammanfattning på svenska .......................................................... viii
Background ........................................................................................ 1 Psoriatic Arthritis ............................................................................................................. 1 Classification and diagnostic criteria ............................................................................... 1 Disease expression ............................................................................................................ 1 Treatment.......................................................................................................................... 5
Pharmacological treatment; ..................................................................................... 5 Treatment goals ........................................................................................................ 6
Epidemiology .................................................................................................................... 7 Aetiology .......................................................................................................................... 8
The immune system ................................................................................................... 8 Soluble biomarkers .................................................................................................. 13 Genetics of Pso and PsA ........................................................................................... 15
Prognosis ........................................................................................................................ 20 Co-morbidity .................................................................................................................. 20
Aims ................................................................................................ 23
Patients and Methods ...................................................................... 24 Patients and controls ..................................................................................................... 24 Clinical characteristics .................................................................................................... 27 Laboratory tests ............................................................................................................. 29
Genotyping .............................................................................................................. 29 Measurement of serologic biomarkers .................................................................. 30
Statistical analysis.......................................................................................................... 30
Study design .................................................................................... 32 Paper I ............................................................................................................................ 32 Paper II........................................................................................................................... 32 Paper III ......................................................................................................................... 32 Paper IV ......................................................................................................................... 33
Results and discussion .................................................................... 34 Genetic analyses (Papers I and II) ................................................................................ 34 Analysis of biomarkers (Paper III) ............................................................................... 39
Variables reflecting disease activity at clinical examination ............................... 40 Serological biomarkers in relation to disease phenotypes ................................... 43
Investigation of mortality, cause of death and incidence of acute cardiovascular disease
in patients with PsA compared with the general population (Paper IV) ..................... 45 Mortality and cause of death .................................................................................. 45 Factors associated with death in PsA patients ...................................................... 46 Cardiovascular Events ............................................................................................ 48
ii
Factors associated with CVE among PsA patients ............................................... 48 Concluding remarks ....................................................................................................... 51
Conclusions ..................................................................................... 53
Future perspectives ......................................................................... 54
Acknowledgements ......................................................................... 56
References ...................................................................................... 58
iii
Abstract
Psoriatic Arthritis (PsA) is a heterogonous inflammatory arthritis associated with
psoriasis. The disease leads to inflammation of peripheral joints, axial skeleton
and/or enthesites, and can result in severe destruction of affected joints. In
contrast to rheumatoid arthritis (RA), most individuals with PsA are sero-
negative for rheumatoid factor (RF) and/or anti-citrullinated protein/peptide
antibodies (ACPA) and the distal interphalangeal (DIP) joints are often involved.
Dactylitis, a diffuse swelling of an entire digit (finger or toe), is also common.
Traditional markers of systemic inflammation, such as erythrocyte sedimentation
rate (ESR) and/or C-reactive protein (CRP) are elevated in only 50% of the
individuals with PsA. Underlying genetic factors are considered important for
the aetiology, disease expression and prognosis of PsA. To date no specific
biomarker for PsA disease or disease activity/severity is available and there is a
need for diagnostic and prognostic tools to meet the challenge of early diagnosis
and assessment of disease severity.
An increased risk of co-morbidity, particularly cardiovascular disease (CVD), has
been demonstrated in patients suffering from different rheumatic diseases, e.g.
systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Corresponding data for patients with PsA are more limited, but evidence exists
for an increased risk of mortality and cardiovascular morbidity. However,
published results are conflicting and heterogeneity among studies makes
interpretation of data difficult.
The aim of this study was to investigate genetic and serological biomarkers, and
also mortality and cardiovascular comorbidity, in different phenotypes of PsA
and in comparison with healthy controls.
Patients with PsA were included between 1995 and 2015, the majority from the
county of Västerbotten, except for two cohorts from Örnsköldsvik (n=55) and
Östersund (n=98).
The genetic polymorphism PTPN22+1858C/T, previously found to be associated
with several autoimmune diseases, was also found associated with PsA, the
results were later confirmed in a genome wide association study (GWAS).
Additionally, among PsA patients, the minor allele, T, was associated with the
number of deformed joints and dactylitis (Paper I).
Genetic polymorphisms in genes related to the inflammasome were also
investigated, both in comparison with healthy controls and in relation to different
phenotypes of PsA (Paper II). An association was identified between patients with
iv
PsA and the polymorphism CARD8-C10X in comparison with controls. In
addition, associations between various inflammasome polymorphisms and
different clinical phenotypes of PsA were detected.
To investigate the relation of serological biomarkers and PsA, individuals with
blood samples collected in conjunction with clinical investigation were selected
(Paper III). Associations with different biomarkers and different clinical
phenotypes of PsA were identified In addition, associations were found with
different biomarkers and patients with moderate/high disease activity at clinical
investigation, confirming the inflammatory nature of the disease.
Mortality and incidence of acute cardiovascular disease were investigated with
standardized mortality rate-ratio (SMR) and standardized incidence ratio (SIR)
compared with the general population of Västerbotten (Paper IV). An increased
SMR for diseases of the circulatory system in PsA compared with controls was
found. Among PsA patients, death was associated with a composite disease
activity index (DAI) and with a disease phenotype including both axial- and
peripheral joint involvement.
In conclusion, associations were found with different clinical phenotypes of PsA,
both with genetic polymorphisms and serological biomarkers that confirm the
inflammatory nature of the disease and illustrate the disease heterogeneity. As in
many other inflammatory diseases, an increased cardiovascular mortality was
found that highlights the importance of considering cardiovascular risk factors in
patients with PsA.
v
Abbreviations
ACPA Anti-citrullinated protein/peptide antibodies ACR American Collage of Rheumatology AIM Absent in melanoma APC Antigen presenting cell AS Ankylosing spondylitis ASC Apoptosis-associated speck-like protein containing a C-terminal
caspase recruitment domain B-cell B-lymphocyte BcR B-cell receptor bDMARD Biologic disease modifying anti-rheumatic drug bFGF Basic fibroblast growth factor BMI Body mass index CARD8 caspase recruitment domain-containing protein 8 CASPAR Classification criteria for psoriatic arthritis CCL Chemokine of CC family CD Cluster of differentiation CI Confidence interval CLP Common lymphoid progenitor cell COMP Cartilage oligomeric matrix protein CPII:C2C C-propeptide of Type II collagen (CPII): collagen fragment
neoepitopes Col2-3/4(long mono) (C2C) CRP C-reactive protein csDMARD Conventional synthetic disease modifying anti-rheumatic drugs CTL Cytotoxic T-cell CVD Cardiovascular disease CVE Cardiovascular event CXCL Chemokine of CXC family DAI Disease activity index DAMP Danger-associated molecular pattern DIP joint Distal interphalangeal joint DMARD Disease modifying anti-rheumatic drug EGF Epidermal growth factor ESR Erythrocyte sedimentation rate ET-1 Endotelin-1 EULAR European league against rheumatism FCAS Familial cold-induced auto-inflammatory syndrome FGF Fibroblast growth factor Flt-1 Fms-like tyrosine kinase 1 G-CSF Granulocyte-colony stimulating factor GM-CSF Granulocyte macrophage-colony stimulating factor GRAPPA Group for research and assessment of psoriasis and psoriatic arthritis GWAS Genome wide association study HAQ Health assessment questionnaire HLA Human leukocyte antigen HT Hypertension IBD Inflammatory bowel disease ICAM Intercellular adhesion molecule ICD International classification of diseases IFN Interferon IL Interleukin IL-1ra Interleukin 1 receptor antagonist
vi
ILC Innate lymphoid cells IP-10 Interferon gamma-induced protein 10 (CXCL10) ITGβ5 Integrin-β5 M2BP Mac-2-binding protein MCP joint Metacarpophalangeal joint MDA Minimal disease activity MHC Major histocompatibility complex MIP Macrophage inflammatory protein MMP Metalloproteinase MRI Magnetic resonance investigation MTP joint Metatarsophalangeal joint MWS Muckle-Wells syndrome NK-cell Natural killer cell NLR NOD-like receptor NLRP1 NOD-like receptor family, pyrin domain containing 1 NLRP3 NOD-like receptor family, pyrin domain containing 3 NSAID Non-steroidal anti-inflammatory drug OPLS-DA Orthogonal partial least squares discriminant analysis OR Odds ratio PAMP Pathogen-associated molecular pattern PASI Psoriasis area and severity index PIGF Placental growth factor PIP joint Proximal interphalangeal joint PPP Pustulosis palmoplantaris PROM Patient related outcome measure PsA Psoriatic arthritis Pso Psoriasis of the skin PTPN22 protein tyrosine phosphatase non-receptor 22 RA Rheumatoid arthritis RANKL Receptor activator of nuclear factor kappa-Β ligand RF Rheumatoid factor SAA Serum amyloid A SAPHO Synovitis acne pustulosis hyperostosis syndrome SI-joint Sacro-iliaca joint sICAM Soluble intercellular adhesion molecule SIR Standardized incidence rate ratio SLE Systemic lupus erythematosus SMR Standardized mortality rate ratio SNP Single nucleotide polymorphism SpA Spondylarthropathy STAT Signal transducer and activator of transcription SwePsA Swedish Early Psoriatic Arthritis Register T1D Type-1-diabetes T-cell T-lymphocyte TcR T-cell receptor TH T helper cell Tie-2 Tyrosine kinase 2 TNF Tumour necrosis factor TREG Regulatory T-cell tsDMARD Targeted synthetic disease modifying anti-rheumatic drug uSpA Undifferentiated spondylarthropathy VCAM Vascular cell adhesion molecule VEGF Vascular endothelial growth factor χ2 Chi-square
vii
List of papers
The thesis is based on the following papers that will be referred to by their roman
numerals:
I. Kristina Juneblad, Martin Johansson, Solbritt Rantapää-Dahlqvist
and Gerd-Marie Alenius. Association between the PTPN22+1858 C/T
polymorphism and psoriatic arthritis. Arthritis Res Ther 2011;13:R45
II. Kristina Juneblad, Linda Johansson, Solbritt Rantapää-Dahlqvist and
Gerd-Marie Alenius. Association between inflammasome-related
polymorphisms and Psoriatic arthritis. Manuscript
III. Kristina Juneblad, Solbritt Ranstapää-Dahlqvist and Gerd-Marie
Alenius. Expression of biomarkers in relation to disease manifestations
of Psoriatic Arthritis. Submitted
IV. Kristina Juneblad, Solbritt Ranstapää-Dahlqvist and Gerd-Marie
Alenius. Disease activity and increased risk of cardiovascular death
among patients with Psoriatic Arthritis. J Rheumatol 2016;43:2155-61.
Papers I and IV are reprinted with the kind permission of the publishers.
viii
Sammanfattning på svenska
Psoriasisartrit (PsA) är en inflammatorisk ledsjukdom associerad med
hudsjukdomen psoriasis (Pso). PsA har en mångfacetterad sjukdomsbild med
inflammation i leder, rygg och/eller entesit (inflammation där ligament, senor
och ledkapslar fäster i benet) och kan leda till destruktion av drabbade leder med
påverkan på funktion och livskvalitet. Till skillnad från reumatoid artrit (RA) är
reumatoid faktorn (RF) samt antikroppar mot citrullinerade proteiner (ACPA)
vanligen negativa och det är vanligt att de yttersta lederna i fingrar och tår (DIP-
lederna) drabbas. Vanligt förekommande är också inflammation i ett helt finger
eller tå, s.k. daktylit. Traditionella markörer för sjukdomsaktiviteten mätt med
sänka (SR) och CRP är endast förhöjda hos ca 50 % av individer med PsA.
Bakomliggande genetiska faktorer som reglerar immunologiska och möjligen
också vaskulära uttryck anses vara av betydelse för etiologi, sjukdomsuttryck och
prognos vid Pso och PsA, med en betydande riskökning (ca 40 gånger ökad risk)
att insjukna i PsA om man har en förstagradssläkting med sjukdomen. I nuläget
finns inga tillgängliga biomarkörer för att mäta sjukdomsaktivitet och förutse
sjukdomsförlopp, varken genetiska eller serologiska, och det finns ett stort behov
av diagnostiska och prognostiska faktorer för att ställa tidig diagnos och bedöma
sjukdomens svårighetsgrad.
Under senare år har studier visat på en ökad risk för samsjuklighet, särskilt vad
gäller kardiovaskulär sjukdom, hos patienter med reumatologiska sjukdomar,
som t ex systemisk lupus erytematosus (SLE) och RA. Det finns färre studier
avseende PsA, men det finns stöd för att patienter med Pso och PsA har en ökad
samsjuklighet med engagemang av andra organsystem än hud och leder och en
översjuklighet och överdödlighet i kardiovaskulära sjukdomar. Resultaten är
dock inte entydiga och det finns en stor skillnad mellan olika studier och
studieupplägg som försvårar tolkningen av data.
Syftet med denna avhandling var att studera genetiska och serologiska markörer
samt dödlighet och kardiovaskulär samsjuklighet hos patienter med PsA, både i
jämförelse med friska kontroller och vid olika sjukdomsuttryck av PsA.
I studierna ingår totalt 856 individer med PsA som inkluderats mellan 1995-2015.
De flesta individerna är från Västerbotten, men två delpopulationer från
Östersund (n=98) och Örnsköldsvik (n=55) ingår i studie II.
Studie I och II innehåller den genetiska delen av studien. I delarbete I
undersöktes den genetiska polymorfin, PTPN22+1858C/T som tidigare visat
association med olika autoimmuna sjukdomar. Resultaten visade en association
ix
mellan PTPN22+1858 C/T och PsA i jämförelse med kontroller och bland
patienterna med PsA syntes en association med daktylit och antal deformerade
leder, vilket skulle kunna tyda på en koppling till en svårare sjukdomsbild.
Associationen mellan PTPN22+1858C/T och PsA har senare bekräftats i en stor
genome wide association study (GWAS). I studie II undersöktes olika genetiska
polymorfier i gener relaterade till det interleukin 1β-reglerande
proteinkomplexet, inflammasomen som under senare år har visat intressanta
kopplingar till olika inflammatoriska sjukdomar, t ex RA och Pso. Resultaten
visade association mellan en av polymorfierna, CARD8-C10X och PsA i
jämförelse med kontroller och resultaten visade också association mellan
polymorfier i andra inflammasomgener och olika sjukdomsmanifestationer av
PsA.
För att undersöka serologiska biomarkörer valdes de individer ut som hade
lämnat blodprover i samband med klinisk undersökning (Studie III). Trettionio
olika serologiska biomarkörer analyserades och jämfördes med olika
sjukdomsuttryck hos PsA patienterna och också i jämförelse med friska
kontroller. Resultaten visade association mellan olika biomarkörer och olika
sjukdomsmanifestationer, t ex PsA som involverar ryggen (axial sjukdom), PsA
som engagerar många leder (polyartrit) och PsA patienter som förskrivits
biologiskt läkemedel. Resultaten visade också association för några biomarkörer
och måttlig till hög sjukdomsaktivitet, vilket bekräftar PsA sjukdomens
inflammatoriska natur.
I studie IV undersöktes dödlighet, dödsorsaker och incidensen av akut hjärt-
/kärlsjukdom (akut hjärtinfarkt och stroke) i jämförelse med
normalbefolkningen i Västerbotten. Resultaten visade en ökad dödlighet (SMR) i
cirkulationsorganens sjukdomar (ICD kod; I00-I99) hos patienter med PsA
jämfört med kontroller. Hos PsA patienterna var sjukdomsaktiviteten mätt med
ett kompositindex, DAI, associerat med ökad dödlighet och resultaten visade
också association till en sjukdom med engagemang av både rygg och perifera
leder, som möjligen indikerar en ökad sjukdomsbörda.
Sammanfattningsvis visar resultaten av studierna i denna avhandling på
intressanta associationer till olika kliniska sjukdomsuttryck hos PsA patienter,
både för genetiska polymorfier och serologiska biomarkörer. Resultaten
bekräftar den inflammatoriska naturen hos PsA och illustrerar sjukdomens
heterogenitet och komplexitet. Som vid andra inflammatoriska sjukdomar
noterades ökad dödlighet i cirkulationsorganens sjukdomar, vilket stärker
behovet av att beakta och behandla kardiovaskulära riskfaktorer hos individer
med PsA.
x
1
Background
Psoriatic Arthritis
Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease
associated with cutaneous psoriasis (Pso) (Boehncke and Schon 2015). The
disease was probably first described in 1818 by Alibert (Moll and Wright 1973),
but it was not until 1964 that PsA was recognized as a separate disease by the
American Rheumatism Association (now the American College of Rheumatology)
(ACR) (Coates and Helliwell 2017).
Classification and diagnostic criteria
Due to similarities among the diseases, PsA is classified among the sero-negative
spondylarthropathies (SpA) including ankylosing spondylitis (AS), reactive
arthritis, arthritis and spondylitis associated with inflammatory bowel disease
(IBD) and undifferentiated spondylarthropathy (uSpA) (Dougados, van der
Linden et al. 1991). Due to the heterogeneity of the PsA disease and overlap in
disease pattern between other inflammatory arthropathies, disease classification
and diagnostic criteria have been a topic of debate. The initial criteria proposed
by Moll and Wright in 1973, defined PsA as an inflammatory arthritis in the
presence of psoriasis with usually an absence of rheumatoid factor (Moll and
Wright 1973). In the Moll and Wright criteria, PsA is divided into five sub-groups
defined by disease characteristics (Table 1). In most cases of PsA, psoriasis skin
disease (Pso) precedes the onset of joint disease, but in approximately 10-15%
skin disease develops after the onset of musculoskeletal symptoms (Coates and
Helliwell 2017) and in these cases the Moll and Wright criteria does not apply.
Additionally, PsA can present with polyenthesitis without arthritis, and neither
in these cases, the Moll and Wright criteria apply. Therefore, new consensus
criteria have been developed, e.g. the Classification Criteria for Psoriatic Arthritis
(CASPAR), and these criteria are now being applied in most clinical studies
(Taylor, Gladman et al. 2006) (Table 2).
Disease expression
Psoriatic arthritis is a heterogeneous inflammatory arthritis, with a varied disease
pattern, not only between patients, but also within an individual patient over
time. Disease expression can vary from a mild mono-/oligoarthritis to severe
erosive polyarthritis comparable with rheumatoid arthritis (RA), with or without
involvement of the axial joints and/or manifestations such as enthesitis and
2
dactylitis (Moll and Wright 1973, Dougados, van der Linden et al. 1991, Helliwell
2009). Contrary to RA, PsA disease often include DIP-joint arthritis. Also in
contrast with RA, most individuals with PsA are sero-negative for rheumatoid
factor (RF) and anti-citrullinated protein/peptide antibodies (ACPA) (Alenius,
Berglin et al. 2006, Taylor, Gladman et al. 2006).
Table 1. The Moll and Wright criteria for PsA
Main criteria; Presence of skin psoriasis in combination with
inflammatory articular disease affecting peripheral
joint and/or spine. Rheumatoid factor (RF) usually
negative.
Sub-classes according to
Moll & Wright
- DIP joint disease Exclusive DIP-joint involvement
- Axial disease Predominantly axial disease
- Mono-/oligoarthritis Involvement of ≤ 4 joints when clinically active PsA
disease
- Polyarthritis Involvement of ≥ 5 joints when clinically active PsA
disease
- Arthritis mutilans Severe, erosive, mutilating disease phenotype
Table 2. The Classification criteria for Psoriatic Arthritis (CASPAR) criteria
(Taylor, Gladman et al. 2006)
Main criteria: Documented inflammatory articular disease (joint, spine or entheseal).
+ ≥ 3 points of the following additional criteria
Active skin psoriasis (2p), own history of psoriasis (1p) or a first- or second degree relative with psoriasis (1p)
Typical psoriatic nail changes, including onycholysis, pitting or hyperkeratosis (1p)
Negative test for rheumatoid factor (RF), latex not included. (1p)
Either current dactylitis, defined as swelling of an entire digit, or a history of dactylitis recorded by a rheumatologist (1p)
Radiographic evidence of juxta-articular new bone formation, appearing as ill-defined ossification near joint margins (but excluding osteophyte formation) on plain radiographs of the hand or foot (1p)
3
Since PsA does not always present with increased inflammatory parameters,
erythrocyte sedimentation rate (ESR) and/or C-reactive protein (CRP) is elevated
in only approximately 50% of cases (Gladman, Shuckett et al. 1987, Coates and
Helliwell 2017) and no serological markers for disease are known, it is difficult in
early stages of disease to predict the severity of disease or its progress.
Psoriasis skin disease is also highly variable. Five types of skin psoriasis have been
described; the most common being plaque psoriasis (psoriasis vulgaris) (90% of
Pso); the others being guttate psoriasis; invers psoriasis (intertriginous or
flexural), occurring in skin folds; pustular psoriasis, either pustulosis palmo-
plantaris (PPP) or generalised pustular psoriasis; and erythrodermic psoriasis, a
rare but serious condition (Boehncke and Schon 2015).
Although, among patients with Pso, a more severe skin disease is a risk factor for
developing PsA (Scarpa, Oriente et al. 1984, Gelfand, Gladman et al. 2005,
Wilson, Icen et al. 2009), most patients with PsA have a mild or moderate skin
disease (Cohen, Reda et al. 1999). In addition, approximately 10-15% develop
arthritis prior to Pso and given the heterogeneity in disease expression, differing
PsA from other arthropathies, e.g. RA can be difficult in those cases. Extensive
clinical examination of the skin is essential to discover Pso in hidden places such
as the scalp, peri-umbilical area and natal cleft. Psoriatic nail disease, e.g. pitting,
onycholysis and hyperkeratosis is also common in PsA (Coates and Helliwell
2017). Interestingly, scalp lesions, nail dystrophy and intergluteal/perianal
lesions have been found most likely to be associated with the development of PsA
among patients with Pso (Wilson, Icen et al. 2009). Another challenge in the
diagnosis of PsA, especially among patients with Pso, is to differentiate between
an inflammatory arthritis and osteoarthritis/mechanical pain and between
polyenthesitis in PsA and fibromyalgia (Mease 2011, Eder, Polachek et al. 2017,
Marchesoni, De Marco et al. 2018). Moreover, early diagnosis is important,
especially in the case of destructive disease phenotype, to prevent the structural
damage that can occur early in the disease (Theander, Husmark et al. 2014,
Haroon, Gallagher et al. 2015).
Radiological findings in PsA are different from those associated with RA, and are
a consequence of a combination of bone resorption/erosions, similar to RA, but
also new-bone formation. Typical changes include; whittling of phalanges distal
bone ends, cupping of the proximal bone ends resulting in the typical pencil-in-
cup appearance on radiographs, erosion of terminal phalangeal tufts (acro-
osteolysis), sacroiliitis and spondylitis. Also typical are the lack of symmetry,
predilection for DIP- and PIP joints over MCP/MTP joints and severe destruction
of isolated small joints (Moll and Wright 1973). To detect the early signs of active
inflammation, especially in the spine and sacro-iliaca (SI) joints, Magnetic
Resonance Investigation (MRI) is used.
4
Dactylitis, a diffuse swelling of an entire digit (finger or toe), is a characteristic
feature of PsA with a high specificity for spondylarthropathies, is considered a
marker of disease severity (Brockbank, Stein et al. 2005, Geijer, Lindqvist et al.
2015, Mease, Karki et al. 2017). Dactylitis occurs in approximately 32-48% of
patients with PsA (Liu, Yeh et al. 2014). Imaging with ultrasound and MRI have
shown involvement of soft tissue thickening, tenosynovitis, enthesitis, synovitis
and the palmar/plantar plate in dactylitis (Sakkas, Alexiou et al. 2013,
Ostergaard, Eder et al. 2016) and in the DIP-joints, MRI has visualized
inflammation extending to the nail bed suggesting an association between
enthesitis, dactylitis and the nail (Ostergaard, Eder et al. 2016). Both dactylitis
and psoriatic nail disease are disease phenotypes included in the CASPAR criteria
(Table 2).
It has been hypothesized that the primary inflammatory site of PsA and other
SpAs are the enthesites, the site where tendons, ligaments and joint capsules
attach to bones (McGonagle, Gibbon et al. 1998). Evidence for the hypothesis
comes from radiological and MRI examinations with signs of inflammation, new
bone formation and erosions at entheseal sites, both early and late in the disease
process (McGonagle, Gibbon et al. 1998, Braun, Khan et al. 2000). Enthesitis is
common in patients with PsA with a prevalence of approximately 35% (Gladman
and Chandran 2011, Polachek, Li et al. 2017) and PsA patients with enthesitis
shows greater disease activity, poorer functional status (measured by Health
Assessment questionnaire (HAQ)), greater pain, fatigue and activity impairment
compared with patients without enthesitis (Mease, Karki et al. 2017).
Non-specific musculoskeletal symptoms and pain are common in patients with
Pso and PsA. Patients can present with tender joints and diffuse pain on and
around enthesites, both peripheral and axial, with no objective signs of active
inflammation, such as swelling, redness, heat or signs of active inflammation on
ultrasound or MR-scan of axial skeleton. These symptom occur both in patients
with and without established joint disease. The mechanism for this is unclear.
Recently, among patients with Pso, non-specific musculoskeletal symptoms were
evaluated to assess whether they could predict development of PsA. Joint pain in
women, fatigue and duration of morning joint stiffness and the gradual
worsening of symptoms predicted the development of PsA, but the authors stress
the clinical challenge in separating pain from osteoarthritis and mechanical pain
(Eder, Polachek et al. 2017). Pain is a common symptom in inflammatory arthritis
and has been considered to be mainly of peripheral nociceptive origin (Schaible,
von Banchet et al. 2010). Although in some cases, patients develop pain
hypersensitivity and chronic pain that persists after the inflammation has been
treated (Woolf 2011, Rifbjerg-Madsen, Christensen et al. 2017). In a recent
Danish study, pain was investigated in patients with RA, PsA and SpA, both with
traditional visual analogue scale (VAS) and an index specific for pain with
5
neuropathic features (Rifbjerg-Madsen, Christensen et al. 2017). They found that
50% of the patients had significant pain despite no objective signs of
inflammation and 20% had indications of neuropathic pain and patients with PsA
had a higher frequency of pain with neuropathic features compared with RA
(Rifbjerg-Madsen, Christensen et al. 2017).
Treatment
The complexity and heterogeneity of PsA can lead to challenges in the selection
of treatment. Both the skin and joint disease needs consideration, as does the
associated diseases, such as uveitis and inflammatory bowel disease. Also
important is to consider are the different associated comorbidities, such as
cardiovascular disease (CVD) and metabolic syndrome (Coates, Kavanaugh et al.
2016). Thus, several medical specialties are often involved in the management of
PsA. In addition, physical activity to preserve function and prevent comorbidities
are essential aspect of the basic treatment of PsA and therefore the involvement
of physiotherapists and occupational therapists in the early stages of disease is of
importance.
Pharmacological treatment;
The different disease pattern and severity determines the treatment strategy for
patients with PsA and a step up strategy is usually applied. Recently, new
recommendations from both the European League Against Rheumatism
(EULAR) and the Group for Research and Assessment of Psoriasis and Psoriatic
Arthritis (GRAPPA) have been updated (Coates, Kavanaugh et al. 2016, Gossec,
Smolen et al. 2016, Coates and Helliwell 2017). The overarching principles of the
two publications are similar, but the task forces behind were somewhat different
in composition. The EULAR group consisted almost exclusively of
rheumatologists whilst many members of the GRAPPA task force were
dermatologists resulting in specifically also considering dermatological aspects
such as skin and nail disease while the EULAR task force focused mainly on
musculoskeletal aspects (Gossec, Coates et al. 2016). Thus, the EULAR
recommendations focus on the treatment of the musculoskeletal aspects and
recommend consulting a dermatologist in PsA patients with predominantly skin
disease.
For the musculoskeletal aspects of PsA, the basic treatment, if no
contraindications are evident, is non-steroidal anti-inflammatory drugs
(NSAIDs), used for pain, stiffness and mild cases of inflammation, in initial stages
often combined with intra-articular corticosteroid injections. Oral steroids
should be used with caution due to possible worsening of skin-disease upon
6
cessation. In mild cases of PsA with mono-/oligoarthritic disease pattern the
combination of NSAID and intra-articular injections can be sufficient to control
the disease. If not, or if negative prognostic factors are evident at diagnosis (e.g.
polyarthritic disease, radiographic damage, elevated acute phase reactants,
dactylitis) conventional synthetic disease modifying anti-rheumatic drugs
(csDMARDs) are added to control the disease. Methotrexate is usually the first
choice of csDMARD unless contraindicated. Other used csDMARDs, either as
single treatment or in combinations are sulfasalazine, leflunomide and
cyclosporine, and less commonly intramuscular myocrisin and plaquenil. If
predominantly axial disease, treatment with csDMARDs is not included in either
the EULAR or the GRAPPA recommendation, but in individual cases, csDMARDs
can be beneficial.
If csDMARDs are insufficient or not tolerated, the next treatment step involves
different biological agents (bDMARDs) or a targeted synthetic DMARD
(tsDMARD). The term “biological” referring to the protocol for the production in
different cell types. The most commonly used bDMARDs are different drugs
targeting tumour necrosis factor (TNF), e.g. adalimumab, certolizumab
etanercept, golimumab and infliximab. In recent years, new biological drugs
targeting other molecules have been approved for treatment of PsA.
Ustekinumab, an inhibitor of interleukin (IL)-12/IL-23, originally approved for
Pso, has a good effect on skin disease but is generally considered less effective
than TNF- inhibitors in PsA (Coates and Helliwell 2017) and are thus considered
a second line of biological therapy. Also, based on the presumable importance of
(T helper cell) (TH)17-pathway in PsA-disease several drugs targeting IL-17 have
been developed, e.g. secukinumab and ixekinumab, both being monoclonal
antibodies against IL-17A with effect both on skin and joint disease. Recently, for
the first time in many years, a new oral drug, aprimelast, has been developed. It
is the first tsDMARD developed for PsA, generally considered having lower effect
compared with biological agents, but has a more favourable safety profile (Coates
and Helliwell 2017). Very recently, also another oral drug, a januskinase inhibitor
(tofacitinib), previously approved for RA, was approved for treatment of PsA.
Treatment goals
Treatment of PsA, as in RA, should aim at minimizing disease activity and avoid
long term complications secondary to disease and/or treatment. Recently, an
index to define minimal disease activity (MDA), considering the multiple disease
domains in PsA has been suggested as a treatment target (Coates, Fransen et al.
2010). In MDA, 7 domains are evaluated (tender joint count ≤ 1, swollen joint
count ≤ 1, enthesitis count ≤ 1, Psoriasis Area and Severity Index (PASI) ≤ 1 or
Body Surface Area (BSA) ≤ 3%, Health Assessment Questionnaire (HAQ) ≤ 0.5,
7
patients global VAS (0-100) ≤ 20 and patients pain VAS (0-100) ≤ 15). To achieve
MDA a patient should meet 5/7 criteria and for a patient to be in very low disease
activity an MDA score of 7/7 has been suggested (Coates and Helliwell 2016).
Additionally, in recent years, patient related outcome measures (PROMs), e.g.
fatigue, emotional well-being, sleep, health related quality of life etc have gained
a wider focus (Orbai, de Wit et al. 2017).
Epidemiology
Psoriatic arthritis affects men and women equally (Gladman 1994) with the exact
prevalence of PsA being unknown. Psoriasis of the skin has as a prevalence of 0.6-
4.8 % and varies between populations (Setty and Choi 2007) and of patients with
Pso, 10-45% also has PsA (Moll and Wright 1973, Alenius, Stenberg et al. 2002).
In a previous study (Alenius, Stenberg et al. 2002) the prevalence of PsA among
patients with Pso was investigated. In that study 33% among Pso patients were
diagnosed by a rheumatologist as having peripheral and/or axial arthritis, of
these 45% had not previously been diagnosed (Alenius, Stenberg et al. 2002). In
a very recent meta-analysis, the prevalence of PsA among Pso was investigated
and a pooled prevalence of 19.7% was detected with a higher prevalence of 24.6%
in patients with moderate-to-severe skin disease (Alinaghi, Calov et al. 2018).
The cumulative incidence of PsA among patients with Pso have also been
investigated, where Wilson et al reported a cumulative incidence of 5.1% per 20
years (1970-1999) and Eder et al reported a yearly incidence of 2.8% (2006-
2014). Factors predicting PsA among Pso in the two studies were psoriatic nail
dystrophy, scalp lesions, intergluteal/perianal psoriasis, severe Pso, nail pitting,
uveitis and lower level of education (Wilson, Icen et al. 2009, Eder, Haddad et al.
2016).
A systematic review of articles published until 2006 shows population prevalence
of PsA varying from of 0.02%-0.42% in Europe/America and 0.001% in Japan.
Data on the PsA incidence were fewer and the same study showed incidence rates
ranging from from 0.1/100000 in Japan to 23.1/100000 in Finland (Alamanos,
Voulgari et al. 2008).
In a recent population based study from Denmark, the yearly incidence of PsA
from 1997 to 2011 was investigated (Egeberg, Kristensen et al. 2017). The
incidence increased over time from 7.3/100000 in 1997 to a maximum of
27.3/100000 in 2010, according to the authors, possible explanations to the
increase being greater attention by patients and physicians, availability of
classification criteria and increased awareness of the need for early treatment. In
8
their study, the prevalence in individuals ≥18 years and diagnosed by
rheumatologists was 0.20% (Egeberg, Kristensen et al. 2017).
Aetiology
The precise aetiology of PsA is unknown. Environmental factors such as
streptococcal pharyngitis, medical drugs, stressful life events and physical trauma
are known environmental triggers for Pso. The Köbner phenomenon is a known
factor to develop psoriatic lesions at a site of skin injury and a connection with
physical trauma, reflecting a deep Köbner phenomenon, has been suggested to be
a risk factor for developing inflammatory arthritis in PsA (Pattison, Harrison et
al. 2008).
Synovia from patients with PsA show distinct features compared with those from
patients RA, at both microscopic level, with increased vascularity and fibrosis and
with respect to the cellular infiltrates, and expression of different cytokines
(Espinoza, Vasey et al. 1982, Reece, Canete et al. 1999, Fearon, Griosios et al.
2003). However, biopsies have shown comparable levels of pro-inflammatory
cytokines as in RA (van Kuijk, Reinders-Blankert et al. 2006).
Underlying genetic factors that regulate immunological and possibly also
vascular expression are considered important for aetiology, disease expression
and prognosis in Pso and PsA. A previous population study on the Icelandic
population has shown a significantly increased risk (39 times) of developing PsA,
if a first degree relative has the disease (Karason, Love et al. 2009), which can be
compared with the corresponding risk of developing psoriasis (8 times increased
risk) and RA (3 times increased risk) (Bluett and Barton 2012). Thus, evidence
exists for a strong genetic impact in PsA, making studies in the area of interest.
The immune system
The purpose of our immune system is to protect us from disease, e.g. harmful
pathogens and tumours. The immune system can be sub-divided into the
developmentally more ancient, innate immune system and the evolutionarily
younger adaptive immune system (Hedrich 2016). They are usually described as
two separate systems but a substantial communication between them is essential
for optimal function.
Inflammatory mediators
Cell to cell communication is important for the immune system and an important
role in this communication is mediated by cytokines and chemokines. Cytokines
9
are small proteins that are produced by one cell and affect other cells by binding
to specific receptors on the cell surface. Chemokines are also small proteins with
chemoattractant properties that stimulate migration and activation of different
cell types.
Innate immunity
The innate immune system is first line of defence against pathogens. It is non-
specific, lacks immunological memory but reacts quickly in response to outside
threats. In addition to physical (e.g. skin and mucosa) and chemical barriers (e.g.
anti-microbial substances from epithelia), it includes both cellular and humoral
components involved in detection and elimination of danger signals. Targets can
be of microbial origin and are recognized as pathogen-associated molecular
patterns (PAMPs), but also host molecules, danger-associated molecular patterns
(DAMPs). Cellular components of the innate immune system include monocytes
and macrophages, neutrophilic granulocytes, dendritic cells, natural killer cells
(NK-cells) and the recently discovered innate lymphoid cells (ILCs) (Hedrich
2016, Xiong and Turner 2018).
Innate lymphoid cells
Like antigen-receptor bearing T- and B-cells (described below), ILCs are derived
from common lymphoid progenitor cells (CLP), but they are devoid of any
antigen receptors. The first of these cells to be discovered were the NK-cells that
complements the cytotoxic, Cluster of differentiation (CD)8+ T-cells, in killing
infected, stressed or transformed cells (Eberl, Colonna et al. 2015). Apart from
NK-cells, ILCs are divided in three classes of non-cytotoxic, helper-like ILCs,
differentiated by their cytokine production and the transcription factors that
regulate their development and function. ILC1 cells produce mainly interferon
(IFN)-γ and tumour necrosis factor (TNF) and have been implicated in defence
against intra-cellular bacteria and parasites, ILC2 cells produce TH2-related
cytokines and are implicated in anti-helminth immunity, allergic inflammation
and tissue repair. ILC3 cells produce, depending on the stimulus, interleukin
(IL)-17A, IL17F, IL22, granulocyte macrophage-colony stimulating factor (GM-
CSF) and TNF and can promote anti-bacterial immunity, chronic inflammation
or tissue repair (Artis and Spits 2015). Thus, the different classes of ICLs largely
resembles the different classes of helper T-cells (TH) in the adaptive immune
system (TH1, TH2, TH17) (see below), but lacks corresponding antigen specific
receptors.
10
Adaptive immunity
If the innate immune system fails to clear an invading pathogen, the adaptive
immune system is activated. In contrast to the innate immune system, the
adaptive immune system matures during life, is highly specific, and can provide
long-lasting immunological memory. In addition, the adaptive immune system is
capable of separating self from non-self that, under normal circumstances, leads
to an immune response only to foreign antigens. Cells involved in the adaptive
immune system are T-lymphocytes (T-cells) and B-lymphocytes (B-cells).
B-cells
B-cells develop and mature in the bone marrow. B-cells interact with their
environment through a surface immunoglobulin, the B-cell receptor (BcR). When
naïve B-cells are activated by binding of their specific antigen to the BcR, they
differentiate into antibody producing cells, e.g. plasma cells and memory B-cells.
The main effector function of B-cells is the production of specific antibodies, but
B-cells are also important as cytokine secreting and antigen presenting cells.
T-cells
Like B-cells, T-cells develop in the bone marrow, but unlike B-cells differentiate
and mature in the thymus. All T-cells express the antigen recognizing T-cell
receptor (TcR). Most T-cells in humans express a TcR consisting of a heterodimer
of an α and β-receptor (αβ T-cells), but a smaller proportion consists of the highly
specialized γδ T-cells that is considered a part of the innate immune system
(Attaf, Legut et al. 2015). To be activated, T-cells require two signals, First, the
recognition of a specific foreign antigen presented together with the major
histocompatibility complex (MHC) on an antigen presenting cell (APC) and
secondly interaction of its co-receptor, CD28 (CTLA-4), with co-stimulatory
molecules (e.g. CD80/CD86) on the APC (Harris and Ronchese 1999).
T-cell subtypes
T-cells are sub-divided according to the expression of the co-receptors CD4 and
CD8.
When a CD8+ T-cell binds to and antigen presented on an MHC class I molecule
on an APS, the cell is activated and differentiate to a cytotoxic T-cells (CTL).
CD4+ T-cells recognize antigens presented together with MHC class II molecules
and upon activation differentiate to different T-helper sub-sets depending on the
type of cytokine produced and their immune regulatory function (Mosmann and
11
Coffman 1989, Harrington, Hatton et al. 2005). The TH1 cells mainly produce
IFN-γ and are involved in cell-mediated immunity. TH2 cells mainly produce IL-
4, IL-5, IL-13 and are involved in humoral immunity and allergic responses while
the more recently discovered TH17 cells mainly secrete IL-17A, IL-17F, IL-21 and
IL-22. The differentiation into the different TH sub-sets is mediated by several key
transcription factors (T-bet, signal transducer and activator of transcription
(STAT)-4 for TH1, GATA-3, STAT6 for TH2, and RORC for TH17) (Harrington,
Hatton et al. 2005). TH17 cells have been implicated to have an important role as
a driving force of autoimmune inflammation. The primary cytokine produced by
TH17 cells is IL-17A, a potent pro-inflammatory cytokine that stimulates the
production of IL-1 and TNF from human macrophages, induces secretion of IL-6
and IL-8 in synovial fibroblasts, induces up-regulation of receptor activator of
nuclear factor kappa-Β ligand (RANKL) and also promotes cartilage degradation
by inducing metalloproteinases (MMPs) and proteoglycan depletion (Leipe,
Grunke et al. 2010).
Recently a sub-type of T-cells, the TH9-cells, defined by the production of IL-9
have been described. They develop from naïve T-cells in the presence of TGF-β,
IL-4 and thymal stromal lymphopoitin. These cells have been implicated in
several inflammatory disorders, e.g. atopic diseases, helminth infections and
inflammatory bowel diseases. (Ciccia, Guggino et al. 2016).
Regulatory T-cells (TREG), previously known as T suppressor cells, have an
important role as regulators of the immune system and in immune tolerance.
TREGs are CD4+ T-cells that also express CD25 (IL-2 receptor alfa) (Sakaguchi,
Sakaguchi et al. 1995) and are also defined by the expression of transcription
factor FoxP3 (Fontenot, Gavin et al. 2003).
Auto-inflammation and autoimmunity
The role of the immune system is to protect from diseases or other threats.
Disturbances in the delicate control of this system can instead cause disease.
Autoimmune diseases are mediated by disturbances in the adaptive immune
system, involving autoreactive antibodies or T-lymphocytes. On the other end of
the spectrum of immunological diseases lies the monogenic auto-inflammatory
diseases, involving innate immunity. Most immunological diseases are
considered polygenic, multifactorial diseases and cannot be classified, purely as
being one or the other. In 2006 McGonagle and McDermott proposed a model
for classification of the immunological diseases where diseases are placed in a
continuum with the rare monogenic autoimmune and auto-inflammatory disease
at both ends and the more complex, polygenic diseases in between (McGonagle
and McDermott 2006) (Figur 1). In this model PsA is placed in the middle, and
12
thus considered as a mixed pattern disease involving both innate and adaptive
immunity.
Figure 1. The Immunological Disease Continuum. Published with courtesy of
professor McGonagle.
McGonagle, D., and M. F. McDermott. 2006. 'A proposed classification of the immunological diseases', PLoS Med. 2006 Aug;3(8):e297. doi: 10.1371/journal.pmed.0030297
The immune system in Pso and PsA
Cells from both the innate and adaptive immune system are involved in Pso and
PsA (Diani, Altomare et al. 2015, Coates, FitzGerald et al. 2016). According to
13
current knowledge of the natural history of Pso two phases of disease are
identified; an initiation phase, involving plasmocytoid and myeloid dendritic cells
(DCs) and a maintenance phase, also involving TH-cell of different subsets,
mainly TH1 and TH17 (Lowes, Suarez-Farinas et al. 2014, Diani, Altomare et al.
2015). The first phase is considered initiated by triggering events, e.g.
streptococcal infections, trauma and medication. In the second phase, autocrine
loops involving different T-cells, keratinocytes and the production inflammatory
cytokines result in chronic inflammation. Also in PsA, different T-cells subsets
are involved, but also macrophages are important (Coates, FitzGerald et al. 2016).
Other cells likely important are γδ T-cells and CD8+T-cells, both cell types
reported as sources of IL-17 in the skin and in synovial fluid (Menon, Gullick et
al. 2014, Diani, Altomare et al. 2015). Recently, cells from the innate immune
system, the ILCs, have been investigated in sera from PsA patients. The study
showed skewed ILC-homeostasis and higher numbers of ILC3, a potent producer
of IL-17/IL-22,that also correlated with PsA disease activity (Soare, Weber et al.
2018), highlighting the role of innate immunity in PsA.
Soluble biomarkers
Cytokines and chemokines in PsA
The PsA synovium, like psoriatic skin, is characterized by overexpression of
cytokines, e.g. TNF, INF-γ, IL-1β, IL-6, IL-10, IL-15 and IL-18 (de Vlam, Gottlieb
et al. 2014).
Serological cytokines have been investigated in PsA, and increased levels of IL-6,
IL-1 receptor antagonist (IL-1ra), soluble IL-2 receptor-alpha (IL-2sRα), INFα,
Pentraxin-3, MMP-3, CXCL10 (IP-10), IL-10, IL-13, CCL3 (MIP-1α), CCL4 (MIP-
1β), CCL11 (Eotaxin), epidermal growth factor (EGF), vascular endothelial growth
factor (VEGF) and fibroblast growth factor (FGF) have been reported (Spadaro,
Taccari et al. 1996, Elkayam, Yaron et al. 2000, Szodoray, Alex et al. 2007,
Alenius, Eriksson et al. 2009, Ramonda, Modesti et al. 2013, Abji, Pollock et al.
2016).
Soluble biomarkers are attractive as diagnostic tools due to their easy accessibility
in patients’ peripheral blood and there are some recent studies in PsA indicating
different biomarkers of relevance. However, for a biomarker to be relevant in
clinical practice it must correlate with disease activity and/or relate to disease
severity, be sensitive to changes in disease activity and/or relevant as a tool in
differentiating from closely related diseases. So far, several biomarkers have been
suggested in PsA, but as yet, none have reached clinical practice (Villanova, Di
Meglio et al. 2013).
14
Serological biomarkers as diagnostic tool and as markers for disease activity
In a Norwegian study by Szodoray et al., 23 soluble cytokines were investigated
in 43 PsA patients with polyarthritic phenotype and 25 healthy controls. In their
study significantly increased serum levels of INF-α, IL-10, IL-13, CCL3 (MIP-1α),
CCL4 (MIP-1β), CCL11 (Eotaxin), EGF, VEGF and FGF was detected in PsA and
G-CSF was decreased. Patients were also sub-grouped according to disease
activity, defined by the number of swollen joints at investigation and IFNα, IL-15
and IL-2 were able to discriminate between the three groups. They also
investigated combinations of cytokines and their differences between PsA and
controls and among PsA with different disease activity. With their model, the
factors best discriminating PsA from controls were IL-2, IL-12p40, IL-15, TNF-α,
MIP-1β, MIP-1α, IFN-α, FGF and Eotaxin and by using a discriminant function
analysis, EGF, INF-α, VEGF, MIP-1α and IL-12p40 discriminated between
controls and sub-sets of PsA with different disease activity (Szodoray, Alex et al.
2007). Also, in a small study by Fink et al. significantly higher concentration of
VEGF was detected in PsA with active disease (defined as ≥ 3 swollen and tender
joints) in comparison with inactive PsA and in healthy controls (Fink, Cauza et al.
2007).
In a study of Hansson and collegues, levels of S-Calprotectin (S-Cal) and CRP
were associated with PsA compared with controls in both mono-oligo arthritis
pattern and polyarthritic disease, with higher levels in PsA with a polyarthritic
disease pattern. In contrast, no associations were found for PsA with the other
cytokines and chemokines investigated (IL12, IL15, IL-16, IL17A, IL-18, IL22, IL-
33, CCL20, CXCL10 (IP-10) and CXCL12), but IL-12, IL-15, IL17A, IL-22, IL-33
correlated with number of tender joints (Hansson, Eriksson et al. 2014). Also, in
a study on clinically active PsA patients, S-calprotectin better related to
radiographic changes than ESR or CRP and also associated with moderate/high
disease activity (physicians’ global assessment and ≥3 swollen joints), but not
better than ESR or CRP (Madland, Larsen et al. 2007).
In two recent studies of Przepiera-Bedzak and co-workers different soluble
biomarkers (Il-18, soluble intercellular adhesion molecule-1 (sICAM-1), fetuin-A,
endotelin-1 (ET-1), IL-6, IL-23, VEGF and EGF have been investigated in patients
with different spondylarthropathies. In the first study, serum-levels of patients
were compared with those in healthy controls and associations were found for
levels of IL-18 and ankylosing spondylitis (AS), PsA, and synovitis acne pustulosis
hyperostosis syndrome (SAPHO) and also correlated with the levels of CRP,
VEGF and total cholesterol. In the second study, extra-articular manifestations
(acute anterior uveitis, IBD, skin psoriasis (Pso), psoriatic onycholysis and PPP)
was investigated, and their conclusion was that SpA-patients with increased
serum IL-18 and decreased ET-1 had an increased risk of extra-articular
15
symptoms (Przepiera-Bedzak, Fischer et al. 2016, Przepiera-Bedzak, Fischer et
al. 2016).
Different biomarkers in relation to treatment response in PsA have also been
studied. For example, in a study on 43 PsA-patients eligible for treatment with
TNF-inhibitors, baseline serum levels of MMP-3, VEGF and CRP were
significantly higher compared with healthy controls and the levels were reduced
after treatment with etanercept (Ramonda, Modesti et al. 2013). Also, in a study
by Chandran et al., levels of MMP-3 correlated with the response to treatment
with TNF-inhibitors and treatment response also correlated with a decrease in
MMP-3 and cartilage oligomeric matrix protein (COMP) after treatment
(Chandran, Shen et al. 2013).
Biomarkers to predict PsA in Pso
In a previous study, where patients with Pso with and without inflammatory joint
disease were compared, the levels of IL-6 was significantly higher in patients with
inflammatory joint disease, irrespective of elevated ESR and/or CRP (Alenius,
Eriksson et al. 2009). In addition, IL-6 levels were associated with polyarthritic
disease and dactylitis. CXCL10 (IP-10) has also been investigated as a potential
marker for PsA among patients with Pso (Abji, Pollock et al. 2016) and was found
in a higher serum concentration at baseline in Pso patients that later developed
PsA. In addition, in a pilot study from Chandran et al, serum levels of CRP,
osteoprotegerin, MMP-3 and C-propeptide of Type II collagen : collagen
fragment neoepitopes Col2-3/4(long mono) (CPII:C2C) ratio were markers for
PsA in patients with Pso (Chandran, Cook et al. 2010).
Thus, to date, the relevance of several biomarkers is indicated, but so far, studies
are few and often with few PsA cases included and further investigations in the
area is important.
Genetics of Pso and PsA
In recent years, genome-wide association studies (GWASs) have profoundly
expanded knowledge among genetic association in both Pso and PsA. Many loci
are common for both diseases, not surprisingly, since most patients with PsA also
have skin disease. However, the substantial difference in degree of heritage
makes it plausible that genetic loci exist that adds a risk of developing joint
disease.
The area most studied is the MHC region on chromosome 6, in which, through
linkage- and association studies, strong association with human leukocyte
16
antigen (HLA)-Cw6 and HLA-B alleles has been found, most of which are
associated with both Pso and PsA, whilst some seems to have a stronger
association with PsA (HLA-B27 and HLA-B7) (Chandran 2013). In addition, an
association with PsA in comparison with healthy controls was detected for the
TNF-B locus within the HLA-region (Alenius, Friberg et al. 2004). Associations
with genes outside the MHC region with both Pso and PsA have also been
identified, e.g. variants of IL12B and IL23R (Filer, Ho et al. 2008). In recent
years, several GWASs have been made, of which so far four on PsA (Cargill,
Schrodi et al. 2007, Liu, Helms et al. 2008, Huffmeier, Uebe et al. 2010, Stuart,
Nair et al. 2015). These studies confirmed previously known associations with
HLA-C and IL12B locus, and in one of these studies a previously unknown
association with TRAFAIP2 was found. This study was performed as a European
collaboration in which parts of the PsA-population included in this study was
included (Huffmeier, Uebe et al. 2010). A later study within the same project has
also shown significant association to another polymorphism in RUNX3 locus
(Apel, Uebe et al. 2013).
PTPN22
The protein tyrosine phosphatase non-receptor 22 (PTPN22) belongs to a family
of protein phosphatases (PTPs), that functions as regulators of tyrosine
phosphorylation-based cell signal transduction. The PTPN22 gene, located on
chromosome 1p13, codes for a non-receptor PTP only expressed by hematopoietic
cells (Stanford and Bottini 2014). PTPN22 is an intra-cellular protein with three
domains, an N-terminal PTP catalytic domain, an inter domain region and a C-
terminal domain with four proline-rich regions that function in interaction with
other proteins (Stanford and Bottini 2014).
PTPN22 is considered as having different roles in immune signalling. In the
adaptive immune system, T-cell receptor signalling is inhibited by
dephosphorylation of key mediators. The function of PTPN22 in B-cells is less
clear, but different roles in B-cell signalling have been suggested. By contrast, in
innate immunity, PTPN22 promotes myeloid-cell type-1 IFN production by
enhancing signalling downstream the pattern recognition receptors (Rhee and
Veillette 2012, Wang, Shaked et al. 2013, Bottini and Peterson 2014, Stanford and
Bottini 2014).
The single nucleotide polymorphism (SNP) rs2476601 (+1858C/T), located in
exon 14 of the PTPN22 gene encodes an arginine to tryptophan substitution at
amino acid 620. In 2004 this polymorphism was found associated with an
increased risk of type-1-diabetes (T1D), RA and systemic lupus erythematosus
(SLE) (Begovich, Carlton et al. 2004, Bottini, Musumeci et al. 2004, Kyogoku,
Langefeld et al. 2004) and the polymorphism is today considered a major risk
17
factor for autoimmunity affecting many, but not all, connective tissue
autoimmune diseases (Stanford and Bottini 2014). So far, PTPN22+1858C/T has
strongest associations with autoimmune diseases where autoantibodies have a
role in pathogenesis, e.g. ACPA-seropositive RA (Begovich, Carlton et al. 2004,
Kokkonen, Johansson et al. 2007) and the combination of PTPN22+1858T and
ACPA-positivity was highly specific for the development of RA in pre-patient sera
(Johansson, Arlestig et al. 2006).
The PTPN22+1858C/T has been suggested to be a gain-of-function variant with
increased dephosphorylating capacity (Vang, Congia et al. 2005), but at the
molecular level results are conflicting. The +1858C/T leads to a substitution of
Arginine (Arg) to Tryptophan (Trp) in position 620 in the first proline-rich
domain of the C-terminus that, in T-cells, is involved in the binding of PTPN22
to the intracellular tyrosine kinase Csk. (Bottini, Musumeci et al. 2004). The
substitution has been shown to inhibit the binding to Csk, leading to increased
phosphatase activity with increased suppression of T-cell receptor signalling
(Vang, Congia et al. 2005, Bottini, Vang et al. 2006). At the cellular level the
mechanisms are under investigation (Stanford and Bottini 2014).
The frequency of variant allele PTPN22+1858T varies considerably among
different populations, e.g. in Europe, the allele is found in 2-3 % in Italy and
Sardinia and the frequency increases in the north/east parts to as much as 15% in
Finland. Interestingly, the allele is almost absent in Asian and African
populations, e.g. Begovich et al showed that PTPN22+1858T was not detected in
100 Han Chinese or 21 Africans and the results have been confirmed in other
studies (Begovich, Carlton et al. 2004, Gregersen, Lee et al. 2006).
PTPN22 in Pso and PsA
Compared with RA, few studies have investigated PTPN22 and PsA. Initial
studies on the PTPN22+1858C/T polymorphism and susceptibility to PsA,
showed conflicting results. (Hinks, Barton et al. 2005, Butt, Peddle et al. 2006,
Huffmeier, Reis et al. 2006). In a UK population (Hinks, Barton et al. 2005) no
association was found with PsA and in a German cohort (Huffmeier, Reis et al.
2006) an association with male PsA-patients, but not females, was detected. Also,
in a study on two populations from Canada (Butt, Peddle et al. 2006) an
association with PTPN22+1858C/T was seen in the cohort from Toronto, but not
in the cohort from Newfoundland. Recently, a GWAS confirmed association
between PTPN22 +1858C/T and PsA. (Bowes, Loehr et al. 2015). Interestingly no
association was found with Pso. Thus the PTPN22+1858C/T polymorphism could
partly explain the higher heritage of PsA compared with Pso (Karason, Love et al.
2009, Bluett and Barton 2012).
18
Inflammasomes
In recent years, research on the IL-1β–regulating protein complexes, called the
inflammasomes, have shown interesting associations with various inflammatory
diseases.
Inflammasomes are a group of protein complexes involved in host defence
against microbes and other forms of stress and damage signals, and also has an
important role in inflammation and tissue repair (Strowig, Henao-Mejia et al.
2012). They consist of protein complexes of a NOD-like receptor (NLR) or an
absent in melanoma (AIM)-like receptor, the adaptor molecule apoptosis-
associated speck-like protein that contains a caspase recruitment domain (ASC)
and the effector protein, caspase-1. The NLR/AIM recognize different
inflammation-inducing stimuli, e.g. conserved PAMPs or DAMPs that leads to
assembly of the protein complex and activation of caspase-1 and subsequent
proteolytic cleavage of inactive forms of pro-IL-1β and pro-IL-18 to the active pro-
inflammatory cytokines, IL-1β and IL-18 (Strowig, Henao-Mejia et al. 2012).
Two of the most studied inflammasomes are the NOD-like receptor family, pyrin
domain containing 1, (NLRP1) and NOD-like receptor family pyrin domain
containing 3 (NLRP3). In mice, the NLRP3 inflammasome is composed of the
NLRP3 protein, the adaptor molecule ASC and caspase-1. In human, the NLRP3-
inflammasome also contain an additional molecule, CARDINAL (also named
caspase recruitment domain-containing protein 8 (CARD8) or TUCAN) (Wilson
and Cassel 2010).
Different mutations in genes of NLRP3 are causally associated with rare auto-
inflammatory conditions characterized by fever and excessive IL-1 production,
e.g. Muckle-Wells syndrome (MWS) and familial cold-induced auto-
inflammatory syndrome (FCAS), diseases that respond favourably to the anti-IL-
1 receptor antagonist, Anakinra (Hoffman, Mueller et al. 2001, Hawkins,
Lachmann et al. 2003, Goldbach-Mansky, Dailey et al. 2006). These diseases
represent prototypes of monogenic auto-inflammatory diseases. However, in
recent years, genetic polymorphisms of NLRP3 have been reported to be
associated with autoimmune diseases, e.g. rheumatoid arthritis (RA) (Kastbom,
Verma et al. 2008).
The NLRP1 inflammasomes have also been implicated in human disease, the first
implicated association was for SNPs in NLRP1 with vitiligo related autoimmune
diseases (Jin, Mailloux et al. 2007).
Several single nucleotide polymorphisms in NLRP1 and NLRP3 have been
examined in multiple inflammatory diseases. Of these, the functional mutations
19
CARD8-C10X and NLRP3-Q705K have been studied in several diseases, both
separately and in combination. For example, the combination of the genetic
polymorphisms NLRP3-Q705K and CARD8-C10X showed association with RA
compared with healthy controls (Kastbom, Verma et al. 2008) and the
combination were also found associated with Crohn’s disease in two studies
(Schoultz, Verma et al. 2009, Roberts, Topless et al. 2010). The NLRP3-Q705K
and CARD8-C10X have also shown individual association with several disease,
e.g. Alzheimer’s disease, Celiac disease, Ankylosing spondylitis and
Cardiovascular disease (CVD) (Paramel, Sirsjo et al. 2015). Recently, an
association with stroke was found with the CARD8-C10X polymorphism in a
recessive model (Bai, Nie et al. 2014). In addition, an association was found with
the variant allele of NLRP3-Q705K and stroke in patients with RA (Kastbom,
Arlestig et al. 2015).
The NLRP3-Q705K is a “gain of function” variant leading to excessive IL-1β and
IL-18 production (Verma, Sarndahl et al. 2012). The CARD8-C10X
polymorphism is a nonsense mutation leading to a truncated CARD8 protein.
Functional investigation of CARD8 is complicated by the fact that it is absent in
rodents. Also, a series of isoforms exists that can possibly affect the consequences
of the C10X polymorphism (Bagnall, Roberts et al. 2008) and patients
homozygous for the C10X might therefore have a functional CARD8 protein due
to different isoforms (Paramel, Sirsjo et al. 2015).
Genetic polymorphisms in inflammasome genes of diseases related to PsA
In a study on families with psoriasis, possible associations between CARD8-C10X
and three polymorphisms in the gene for NALP3 (including NLRP3-Q705K) and
psoriasis were examined. In this study, an association with CARD8-C10X in
comparison with controls was detected, and for one of polymorphisms in NLRP3
gene, the rs10733113G allele was significantly over-transmitted to a sub-group of
Pso with a more widespread skin disease (Carlstrom, Ekman et al. 2012).
Recently, also SNPs in the NLRP1-inflammasome have shown increased
transmission to patients with Pso in transmission disequilibrium test in families
with Pso (Ekman, Verma et al. 2014). In a study of patients with ankylosing
spondylitis (AS), an association with the polymorphism CARD8-C10X in
comparison to healthy controls was discovered, whereas no associations were
found with the three examined polymorphisms in the NLRP3 gene and AS
(Kastbom, Klingberg et al. 2013).
To date, only one study has been published in which genetic polymorphisms in
inflammasome genes have been investigated in patients with PsA (Loft, Skov et
al. 2018). In that study no significant associations were found with PsA (Loft,
Skov et al. 2018).
20
Prognosis
PsA disease expression is highly variable, both in disease expression and in
severity (Moll and Wright 1973, Gladman, Shuckett et al. 1987). As opposed to
the initial view of PsA to be relatively benign, studies have shown that PsA is a
destructive and progressive disease that in almost 20% of cases leads to severe
joint destruction and/or deformities (Gladman, Shuckett et al. 1987, Gladman
1994). Indicated negative prognostic factors for a poor outcome are polyarthritic
disease phenotype, increased levels of inflammatory parameters (ESR, CRP),
smoking and a delay in diagnosis (Gladman, Farewell et al. 1995, Alenius, Jidell
et al. 2002, Tillett, Jadon et al. 2013, Theander, Husmark et al. 2014, Haroon,
Gallagher et al. 2015).
A substantial impact of quality of life has also been shown in PsA (Sokoll and
Helliwell 2001, Husni, Merola et al. 2017). In the Swedish Early Psoriatic Arthritis
Register (SwePsA) patients with early PsA (<2 years symptom duration) have
been followed. At the 5-year follow-up prognostic factors were investigated.
Factors with a positive impact on disease course after 5 years were early
diagnosis, preserved function and male gender (Theander et al. 2014). Risk
factors for radiological progression at 5 years were dactylitis and the presence of
radiological damage at baseline and risk factors for early radiographic damage
was male sex (Geijer, Lindqvist et al. 2015).
Co-morbidity
In PsA, like other diseases in the group of SpAs, extra-articular manifestations
occur, e.g. uveitis, IBD, urogenital inflammation. Previous studies have also
shown renal involvement (Alenius, Stegmayr et al. 2001) and increased risk of
migraine (Egeberg, Mallbris et al. 2015) in patients with PsA. Additionally, in
patients with Pso, increased frequency of a number of co-morbidities have been
reported, particularly in patients with a more severe disease, e.g. CVD, diabetes,
obesity, metabolic syndrome , gastrointestinal diseases, kidney disease,
malignancy, infections and mood disorders (Coates, Kavanaugh et al. 2016,
Takeshita, Grewal et al. 2017, Gisondi, Fostini et al. 2018). In a recent study, the
frequency of extra-articular manifestations and their relation to different PsA
manifestations were investigated; 16.3% had bowel involvement, 12.7% had
urogenital involvement and 5.7% had uveitis (Peluso, Iervolino et al. 2015). Both
bowel involvement and ocular involvement were more common in PsA with axial
disease and urogenital involvement more common in males (Peluso, Iervolino et
al. 2015).
21
In addition to an increased frequency of IBD, sub-clinical inflammation has been
detected in the gastrointestinal tract of patients with PsA (Schatteman, Mielants
et al. 1995, Scarpa, Manguso et al. 2000, Lindqvist, Kristjansson et al. 2006).
Recently, an interesting link between the gut and joint was suggested (Ciccia,
Guggino et al. 2016). In their study an increased number of the recently
discovered TH9-cells and increased levels of IL-9 were detected in the gut of PsA
patients and IL-9 was also overexpressed in synovial tissue from patients with
PsA (Ciccia, Guggino et al. 2016).
Cardiovascular disease is the main cause of death in the general population of the
Western world. The major cause of cardiovascular events is atherosclerosis.
Atherosclerosis is a chronic process in the vessel wall that ultimately leads to
plaque formation and CVD. Atherosclerosis has been widely accepted to be
strongly linked to low-grade vascular inflammation (Hansson, Robertson et al.
2006). In the general population, a number of risk factors have been linked to
development of CVD, e.g. hypertension (HT), hyperlipidaemia, increased body
mass index (BMI), diabetes mellitus and smoking (Wilson, D'Agostino et al. 1998,
Yusuf, Reddy et al. 2001).
Among individuals suffering from different rheumatic diseases, e.g. SLE and RA,
both increased mortality and increased risk of cardiovascular comorbidity have
been demonstrated (Wallberg-Jonsson, Ohman et al. 1997, Wallberg-Jonsson,
Johansson et al. 1999, Bengtsson, Ohman et al. 2012). In RA, a meta-analysis
from 2012 shows increased risk of 48% for incident CVD compared with the
general population (Avina-Zubieta, Thomas et al. 2012) that have led to
recommendations of modifying clinical cardiovascular risk scores in individuals
with RA by multiplying the annual risk calculated by SCORE with a factor 1.5
(Peters, Symmons et al. 2010).
Corresponding data on PsA and CVD are more limited, but several studies
indicate that patients with Pso and PsA have increased morbidity and mortality
due to CVD (Gladman, Ang et al. 2009, Tobin, Veale et al. 2010, Ahlehoff,
Gislason et al. 2011, Horreau, Pouplard et al. 2013, Jamnitski, Symmons et al.
2013, Miller, Ellervik et al. 2013, Polachek, Touma et al. 2017).
Considering the link between inflammation and atherosclerosis (Libby, Ridker et
al. 2009), the increased inflammatory burden in rheumatic diseases has been
implicated in the increased risk of CVD. In Pso and PsA, also a high prevalence of
traditional risk factors, e.g. HT, hyperlipidaemia, increased BMI and diabetes
mellitus have been detected (Jamnitski, Symmons et al. 2013, Miller, Ellervik et
al. 2013). The concept of the “psoriatic march” has been suggested. In this model,
psoriatic disease causes systemic inflammation that causes insulin resistance and
endothelial dysfunction leading to atherosclerosis and ultimately risk of
22
cardiovascular events (CVE) (Boehncke and Boehncke 2012). Moreover, an
association with a more severe PsA disease was found among patients with
metabolic syndrome and insulin resistance (Haroon, Gallagher et al. 2014). The
high frequency of traditional risk factors complicates analysis of the role
inflammation due to disease. In a recent study of PsA patients, CVE were
associated with traditional risk factors (hypertension, diabetes) and disease
activity (ESR in women and dactylitis) (Eder, Wu et al. 2016).
An overall increased mortality in patients with PsA has been shown, particularly
in those patients with signs of a severe disease, high ESR values and early signs
of radiological changes (Wong, Gladman et al. 1997, Gladman, Farewell et al.
1998, Gladman 2008, Ahlehoff, Gislason et al. 2011). However, these findings
have not been confirmed in other studies (Coulton, Thomson et al. 1989, Shbeeb,
Uramoto et al. 2000, Gladman 2008, Ogdie, Haynes et al. 2014). Few studies
have examined causes of death in PsA, in these studies leading causes of death
have been circulatory/cardiovascular, respiratory and malignant neoplasms
(Wong, Gladman et al. 1997, Buckley, Cavill et al. 2010, Ogdie, Maliha et al. 2017).
In a study by Haque et al, frequencies of co-morbidities in PsA were compared
with other SpAs and increased risk of malignancy, hypertension, coronary artery
disease, diabetes, hyperlipidaemia and metabolic syndrome was detected in
patients with PsA compared with the other SpAs (Haque, Lories et al. 2016).
Thus, evidence exists for increased risk of mortality and cardiovascular morbidity
in patients with PsA. However, results are conflicting and heterogeneity among
studies makes interpretation of data difficult (Miller, Ellervik et al. 2013,
Polachek, Touma et al. 2017) and further studies are indicated.
23
Aims
Psoriatic Arthritis (PsA) is a complex disease with a heterogeneous disease
expression. In this study different aspects of PsA is explored and the following
aspects are highlighted:
Is there an association with genetic markers that control the
inflammatory process, and can they be linked to disease expression
and/or inflammatory activity in PsA?
Is the presence and/or levels of various biomarkers related to disease
expression/severity of PsA?
Is there an increased risk for comorbidity in PsA, in particular
cardiovascular disease, and if so, is there an association with disease
expression and/or inflammatory activity?
24
Patients and Methods
Patients and controls
Since PsA is a relatively rare disease, the patients were collected over time (1995-
2015). All of the patients were diagnosed with PsA at the Department of
Rheumatology, Västerbotten, gave their written, informed consent, and were
either examined according to a study protocol or by careful reading of patients’
medical record to validate the diagnosis and classify disease. Since data collection
was performed consecutively over time, various sub-populations are included in
different studies depending on when the study was conducted. During 2009-2010
patients who had been diagnosed with PsA at two nearby hospitals in northern
Sweden (Örnsköldsvik and Östersund), were also asked to participate in the
study. These patients were examined and diagnosed with PsA by rheumatologists
at their local clinic. During 2009-2010, those patients’ records were examined to
validate the diagnosis of PsA and blood samples were collected.
A total of 856 patients with PsA is included in Paper I-IV (Table 3). The study
population by year of inclusion is illustrated in Figure 2a and the representation
of the different cohorts in Paper I-IV is illustrated in Figure 2b and Figure 3.
Table 3. Patients with PsA in different studies by year of inclusion.
Paper I Paper II Paper III Paper IV
Population Year of
inclusion
n
1 1995-96 45 41 41 21 40
2 1999-2000 124 120 121 84 121
3 2007-2008 132 130 130 113 101
4 (Örnsköldsvik) 2009 55 0 55 0 0
5 (Östersund) 2010 98 0 98 0 0
6 2010-2011 203 0 80 11 202
7 2015 199 0 199 45 0
Tot, n 856 291 724 274 464
All patients were either examined, or their medical records evaluated using
standardized study protocols and underwent further tests and/or responded to
questionnaires depending on the aim of the specific study. For a majority of study
participants blood samples have been collected. Blood samples were stored at -
80°C.
25
Figure 2. Illustration of the whole study population divided according to a; year
of inclusion, b; Paper I-IV
a.
b.
26
Figure 3. Representation of the different study populations in Paper I-IV.
The control populations were also varied in the different studies. In Paper I
(n=724) and Paper II (n=586), controls were from the Medical Biobank of
Northern Sweden. In Paper III a proportion of healthy, population controls from
Västerbotten (n=30) that had been included in a previous study was used
(Alenius, Berglin et al. 2006). In Paper IV, no control population was included,
instead comparison was made with the statistics on the general population of
Västerbotten available in the National Causes of Death Register in Sweden and
the National Inpatient Care Register in Sweden (www.socialstyrelsen.se).
In Table 4 the age and gender of patients with PsA and controls in the different
studies are illustrated.
27
Table 4. Age and gender of PsA patients and controls in the different studies.
Paper I Paper II Paper III Paper IV
Pat Co Pat Co Pat Co Pat Co
Number, n 291 725 724 586 274 30 464 NA
Female
/male, n
146/145 460/265 387/337 153/434 136/138 15/15 230/234 NA
Mean age,
y±SD
52.2
±13.1
55.6
±12.4
59.4
±12.4
63.4
±9.7
53.6
±12.9
52.4
±17.4
59.5
±13.5
NA
PsA duration,
y±SD
15.2
±11.7
NA NA NA 14.0
±10.4
NA 20.4
±11.1
NA
Pso duration,
y±SD
NA NA NA NA 24.2
±14.8
NA 31.1
±16.4
NA
Pat=PsA patients, Co=controls, NA=not analysed
Clinical characteristics
Since the patient population was included consecutively and the studies differ
significantly in design and purpose, not all clinical data were available for all
individuals. Thus, some variables are unique to some of the studies while others
are available for all patients. Most definitions that are used and in which of the
studies they were applied are listed in Table 5.
Paper IV is based on investigation of patients’ medical records and
questionnaires. The questionnaires for this study included questions about family
history, medical history, current medication, body weight, body height and
smoking status. Unfortunately, many variables were missing from the patients’
medical records and the use of standardized activity indices for PsA and/or SpA
could not be applied. Instead a composite index, DAI, previously used for RA
(Baecklund, Sundstrom et al. 2003), was used (Table 6). The DAI reflects both
clinical activity for peripheral disease and laboratory activity, and also accounts
for this activity over time. A high DAI possibly reflects a more aggressive disease
or lack of effective treatment.
28
Table 5. Definition of different disease characteristics and in which studies they are used
Disease characteristic Applied
in Paper
Definition
Destructive/deforming disease II-IV Either typical, radiological changes, e.g., erosions, juxta-
articular new bone formation and/or irreversible deformations
(e.g., ankylosis, subluxations and/or loss of function or
reduced mobility).
Measurable inflammation
when clinically active PsA
disease
II-III Defined as either elevated levels of CRP (≥10 mg/L) and/or
ESR (≥20 mm/h when clinically active PsA disease according
to the investigating clinician.
Dactylitis I-IV Diffuse swelling of an entire digit, finger or toe.
Axial involvement I-IV Defined based on radiological findings in the sacroiliac joints
(SI-joints) according to the New York criteria (≥ 2) and/or
syndesmophytes, ligamentous ossification, vertebral squaring
and shining corners of the spine and/or positive MRI-findings
of the SI-joints or spine.
Arthritic joints I Number of swollen and tender joint at clinical investigation.
Deformed joints I Number of deformed joints at clinical investigation.
Nail psoriasis I-III Diagnosed by dermatologist or rheumatologist. Onycholysis
and/or pitting.
Psoriasis type I I-III Onset of skin psoriasis before 40 years of age.
Type of psoriasis II Psoriasis vulgaris, inverse psoriasis, guttate psoriasis,
pustulosis palmo-plantaris (PPP), erythrodermia
Enthesitis I-IV Swelling and tenderness over the insertion of achilles tendon
and/or plantar fascia. Criterion in CASPAR criteria.
DMARD II-IV Disease modifying anti-rheumatic drug.
csDMARD II-IV Conventional synthetic DMARD; cyclosporine,
hydroxychlorokine, leflunomide, methotrexate, myocrisin or
sulfasalazine
bDMARD II-IV Biological DMARD; abatacept, adalimumab, certolizumab,
etanercept, golimumab, infliximab or ustekinumab
Smoking status II, IV Never, current or previous.
PsA disease activity at clinical
investigation
III According investigating clinician, including; axial- and
peripheral joint involvements, enthesitis, dactylitis and
laboratory activity, as none, low, moderate, high or maximal.
PsA disease expression (Moll
& Wright)
- DIP joint disease I-IV Exclusive DIP-joint involvement.
- Axial disease I-IV Predominantly axial disease.
- Mono-
/oligoarthritis
I-IV Involvement of ≤ 4 joints when clinically active PsA disease.
- Polyarthritis I-IV Involvement of ≥ 5 joints when clinically active PsA disease.
- Arthritis mutilans I-IV Severe, erosive, mutilating disease phenotype.
PsA disease involvement
- Peripheral disease
only
I-IV No documented axial involvement (see definition above).
- Axial disease only I-IV No peripheral arthritis documented (see definition above).
- Peripheral and
axial disease
I-IV The combination of peripheral arthritis and axial involvement
according to definition above.
Disease Activity index (DAI) IV Table 6
29
Table 6. Disease activity index (DAI)*
Score 1 2 3 ESR 1-20 20-60 >60 Number of swollen and tender joints 0-3 4-6 ≥7 Physicians global assessment of disease activity
none-low Moderate high
*=As described in Baecklund et al. (Baecklund, Sundstrom et al. 2003) for RA, with modification of lowering ESR for score 2 from 30 to 20 mm/h. Values for score was extracted from patients’ medical
record every two years during the whole period of PsA disease (from diagnosis to the end of the
study). The final score was calculated as a mean, range 3-9. For missing data, the method of last observation value carried forward was used.
Laboratory tests
For patients who underwent clinical investigation at inclusion, blood samples
were collected at the time of investigation. When patients medical records were
used to verify diagnosis and disease characteristics, laboratory data were
extracted from medical records. In all papers, erythrocyte sedimentation rate
(ESR, mm/h) and C-reactive protein (CRP, mg/L) were determined using routine
methods. Rheumatoid factor (RF) and anti-citrullinated protein/peptide
antibodies (ACPA) were generally extracted from patients medical record, except
for in study I were RF and ACPA were analysed with ELISA (ORG522 M
Rheumatoid Factor IgM ELISA kit (Orgentic Diagnostika GmbH, Mainz,
Germany) and DIASTAT Anti-CCP ELISA kit FCCP200 from Axis-Shield
Diagnostics Limited (Technology Park, Dundee, Scotland, UK)). In study II, III
and IV, RF was used if analysed according to standardized method, excluding
latex beads.
All patients included in studies I, II and III and the majority of patients in study
IV donated blood. All blood samples were separated into plasma/serum and buffy
coat cells by centrifugation at 4400 x g for 15 min and stored at -80°C. For
individuals who donated blood at the time of investigation (Paper III) sera were
used for analysis of biomarkers (V-plex and ELISA, see below). Genomic DNA
was extracted from EDTA-treated whole blood using the “salting out” method, for
patients included before 2011 (n=445) and for the remaining with the Flexigene
DNA kit (250) (QIAGEN, Germany).
Genotyping
The PTPN22+1858C/T polymorphism (rs2476601) was determined by the
TaqMan® assay using an ABI PRISM 7900HT Sequence Detection System and
30
the SDS 2.1 software (Applied Biosystems, Foster City, CA, USA) according to the
manufacturer’s instructions.
The SNPs in study II, NLRP3 ( rs35829419 (Q705K) , rs10733113, CARD8 (rs
2043211 (C10X)) and NLRP1 (rs8079034, rs878329) was determined with
TaqMan® SNP Genotyping Assay supplied by Applied Biosystems (Foster City,
CA, USA) according to the manufacturer’s instructions. The samples were
analysed on a 7900 HT Fast Real-Time PCR System (Applied Biosystem) by
TaqMan® Allelic Discrimination (Applied Biosystem, Foster City, CA, USA).
Measurement of serologic biomarkers
Sera from patients with PsA and controls were stored in aliquots at -80°C and
analysed by V-plex, 40-plex panel (Meso Scale Discovery (MSD), Meso Scale
Diagnostic, LCC, Rockville, USA) according to the manufacturer’s instructions.
The biomarkers included in V-plex, 40-plex are listed in Table 7. IL-18 and
calprotectin was analysed with ELISA (Invitrogen™ IL-18 Human Platinum
ELISA kit, Thermo Fisher Scientific, Bender MedSystems GmbH, Vienna, Austria
and IDK®Calprotectin Serum/Plasma ELISA, Immundiagnostik AG, Bensheim,
Germany) according to the manufacturer’s instructions.
Table 7. Biomarkers included in the MSD®, V-plex, 40-plex kit®
Panel
Biomarkers included
Vascular injury
panel 2 (human)
Serum amyloid A (SAA), C-reactive protein (CRP), Vascular Cell Adhesion
Molecule-1 (VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1)
Angiogenesis
panel 1 (human)
Vascular endothelial growth factor-A (VEGF-A)*, Vascular endothelial
growth facto-C (VEGF-C), Vascular endothelial growth factor-D (VEGF-D), Tyrosine kinase-2 (Tie-2), Fms-like tyrosine kinase 1 (Flt-1), Placental
Growth Factor (PIGF)*, Basic Fibroblast Growth Factor (bFGF)
Chemokine panel
1 (human)
Eotaxin (CCL11), MIP-1β (CCL4), Eotaxin-3 (CCL26), TARC (CCL17), IP-10
(CXCL10), MIP-1α (CCL3), IL-8 (CXCL8)**, MCP-1 (CCL2), MDC (CCL22),
MCP-4 (CCL13)
Pro-inflammatory
panel 1 (human)
Interferon (IFN)-γ, Interleukin (IL)-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-
12p70, IL-13, Tumour necrosis factor (TNF)-α
Cytokine panel 1
(human)
Granulocyte-macrophage colony stimulating factor (GM-CSF), IL-1α, IL-5,
IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF
*=Due to problems at the manufacturer PIGF and VEGF-A were not included in the analysis.
**=quantitates high levels of IL-8 and was not used in the present analysis
Statistical analysis
Common for all studies: Student’s t-test was used to test for difference in
continuous data. For comparison of categorical data between groups, the Chi-
31
square (χ2) tests was used and for multivariate analysis, logistic regression
analysis were used. Odds ratios (ORs) were caluculated with 95% confidence
interval (CI). For all analysis, p-values were two-sided and a significance level of
≤0.05 was considered significant. Unless otherwise specified, statistical
calculations were performed using PASW Statistics program (SPSS Inc., Chicago,
IL, USA), either version 18.0 (Paper I and IV) or version 24.0 (Paper II and III).
The specific statistical methods used in the individual studies are described in
Table 8.
Table 8. Statistical methods specific for Paper I-IV
Paper I Power calculation was performed using EpiInfo.
Paper II In addition to SPSS 24.0, OpenEpi 3.01 was used. Paper III Orthogonal partial least squares discriminant analysis (OPLS-
DA) was performed using SIMCA-P+ software (version 12.0;
Umetrics AB, Umea, Sweden) to compare PsA with controls and
among PsA between disease phenotypes. In this study, t-tests
were performed with Microsoft Exel 2016, with p-values
adjusted by multiple test correction (pc) according to Benjamini-
Hochberg. Mann-Whitney U tests were analysed by SPSS 24.0.
Paper IV For calculation of standardized incidence ratio (SIR) and
standardized mortality rate ratio (SMR), the expected risk of
death/CVE in the general population in Västerbotten County was
used, stratified for age groups.
32
Study design
Paper I
The first study included in this thesis is a case-control study investigating the
frequency of the PTPN22+1858C/T single nucleotide polymorphism (SNP) in
patients with psoriatic arthritis (PsA) compared with population controls. The
polymorphism had previously been found associated with several autoimmune
diseases, but earlier studies in PsA had shown various results.
In this study, DNA from 291 PsA (146 female, 145 male) from the county of
Västerbotten and 725 population controls were genotyped for the
PTPN22+1858C/T polymorphism and allelic frequencies were compared. Among
PsA allelic frequencies were also examined in relation to different PsA disease
phenotypes.
Paper II
In this case-control study, polymorphisms in different genes related to the
inflammasome were investigated. Five different SNPs were analysed in 724 PsA
patients and allelic frequencies were compared with 587 population controls.
Selection of SNPs was based on previous research on related diseases, e.g.
rheumatoid arthritis (RA) and psoriasis (Pso). Among patients with PsA,
differences in allelic frequencies in different disease phenotypes were also
investigated.
Paper III
The aim of this cross-sectional study was to investigate different serological
biomarkers in relation to different clinical phenotypes of PsA. The study design
was based on the heterogeneity of PsA and lack of serological biomarkers to
predict disease severity. Biomarkers were selected based upon previous findings
in PsA and related diseases.
Two-hundred and seventy-four PsA patients who donated blood in conjunction
with clinical investigation between 1995 and 2015 were included. The study also
included a small number of healthy controls for comparison (n=30). Different
biomarkers were analysed in relation to both PsA disease activity at time of
investigation and to overall PsA disease phenotypes, including whether or not the
patient were treated with anti-rheumatic drugs.
33
Paper IV
In this cohort study, mortality, causes of death and the incidence of acute
cardiovascular events (CVE) in PsA patients were investigated in comparison
with the general population. The background to the study was the previous
findings of increased risk of co-morbidity, in particular CVD, found in several
rheumatic disease, e.g. RA and SLE. Although previous data indicate an
increased risk of CVD in PsA, data is limited and results conflicting.
In the study 464 patients with PsA with established disease were included
between 1995-2005. All patients were diagnosed at the Department of
Rheumatology, Västerbotten, and patients’ medical records were carefully
evaluated according to standardized protocols to verify the diagnosis, and to
record disease activity and disease phenotypes before, during and at the end of
the study and the use of anti-rheumatic drugs.
To investigate mortality and causes of death data was extracted from the National
Causes of Death Register in Sweden until the end of 2011 and to investigate
incidence of CVE (stroke, acute myocardial infarction, and unstable angina
pectoris), data were extracted from the National Inpatient Care Register until the
end of 2010. Standardized mortality rate ratio (SMR) and standardized incidence
rate ratio (SIR) were calculated in comparison with the general population of
Västerbotten.
To investigate the effect of inflammatory activity among PsA patients, a
composite disease activity index (DAI) was used (Table 6). The impact of different
anti-rheumatic treatments and different PsA disease phenotypes on the risk of
death and acute cardiovascular event were also investigated.
34
Results and discussion
The great heterogeneity and complexity of PsA disease is a challenge both in
research studies and in clinical practice. In some aspects, the more we know, the
more complex the picture seems to become. This thesis is the summary of four
studies on well-characterized patients with PsA in a relatively large cohort from
Northern Sweden. In this study, different aspects of PsA have been investigated
and some interesting results generated, but as often happens in research, new
questions arise as others are answered.
Genetic analyses (Papers I and II)
A strong genetic impact is suggested for PsA with an approximately 40-times
increased risk if a first degree relative with the disease (Karason, Love et al.
2009), making genetic studies of interest. Therefore, we wanted to study PsA in
comparison with healthy controls and among different phenotypes of PsA
disease. Studies of different SNPs were chosen based on previous research on
related diseases. Since allelic frequencies often differ between different
geographic areas, we used population controls from the same geographic area as
the patients.
In Paper I an association with the PTPN22+1858C/T polymorphism and PsA
was found, with both an increased carriage of risk allele PTPN22+1858T (CT+TT)
(χ2=6.56, p=0.010, odds ratio (OR) 1.49 (95%CI 1.10-2.02) and an increased
frequency of the T-allele in patients with PsA compared with controls (0.160 vs
0.119, p=0.013). Earlier studies of this polymorphism had shown conflicting
results (Hinks, Barton et al. 2005, Butt, Peddle et al. 2006, Huffmeier, Reis et al.
2006), but recently the association between PTPN22+1858C/T and PsA was
confirmed in a GWAS (Bowes, Loehr et al. 2015). Interestingly, no association
was found with Pso.
Since PTPN22 +1858 C/T had previously been associated with RA, it was decided
to investigate whether patients with PsA who were positive for RF and/or ACPA
contributed to the association. Instead, when RF or ACPA sero-positive patients
were excluded an even stronger association was found (χ2=8.56, p=0.003, OR
1.61 (95%CI 1.17-2.21) and (χ2=6.63, p=0.010, OR 1.51 (95%CI 1.10-2.07)
respectively) (Table 9). In addition, carriage of PTPN22+1858T was similar
among PsA patients with both mono-/oligoarthritic and polyarthritic disease
phenotypes (Table 10). Thus, the association with PTPN22+1858T was not
attributed to PsA with a more RA-like phenotype.
35
Table 9. Comparison of PTPN22+1858C/T genotypes in PsA patients stratified
according to anti-citrullinated protein/peptide antibodies (ACPA) and
rheumatoid factor (RF) with all controls.
CT+TT CC Cases versus controls
n (%) n (%) χ2 P-value OR (95% CI)
All PsA 87 (29.9) 204 (70.1) 6.56 0.010 1.49 (1.10-2.02)
ACPA neg 80 (30.3) 184 (69.7) 6.63 0.010 1.51(1.10-2.08)
ACPA pos 6 (28.6) 15 (71.4) 0.45 0.50 1.39 (0.53-3.64)
RF neg 79 (31.6) 171 (68.4) 8.56 0.003 1.61 (1.17-2.21)
RF pos 8 (23.5) 26 (76.5) 0.26 0.87 1.07 (0.48-2.41)
When patients with different phenotypes of PsA disease were compared, an
association was found between patients with PsA that anytime had been
diagnosed with dactylitis and carriage of PTPN22+1858T (χ2=10.56, p=0.001, OR
2.58 (95% CI 1.44-4.62). Additionally, carriers of PTPN22+1858T had
significantly more deformed joints at examination compared with non-carriers
(mean number of joints ± SEM; 5.9 ±1.2 vs 2.8 ±0.5; p=0.005) (Table 10). The
association with dactylitis and deformed joints indicate an association of
PTPN22+1858T with a more aggressive PsA disease.
In Paper II different SNPs in genes related to inflammasomes were investigated.
We found a significant association with the genotype AA (vs AT+TT) of CARD8-
C10X (rs2043211) for PsA patients compared with controls (χ2=5.77, OR (95%CI);
1.32 (1.05-1.65), p=0.016), with the strongest association compared with controls
in patients with peripheral joint disease without axial involvement (χ2=6.6, OR
(95%CI); 1.36 (1.08-1.72), p=0.010). These results are in agreement with previous
studies on patients with AS (Kastbom, Klingberg et al. 2013) and Pso (Carlstrom,
Ekman et al. 2012). In a previous study on early RA, an association with CARD8-
C10X and inflammatory activity was found (Kastbom, Johansson et al. 2010). In
this study, PsA patients with both short- and longstanding disease were included
and most patients had established disease. Thus, it was not possible to investigate
this polymorphism in relation to PsA disease activity early in disease and among
PsA patients there was no association with a disease phenotype with measurable
inflammation in active disease.
36
Table 10. Comparison of carriage of PTPN22+1858T in different PsA disease
phenotypes and among males and females
CC CT+TT p-value
Arthritic joints (n±SEM) 3.01 (±0.28) 3.18 (±0.41) 0.73 Deformed joints (n±SEM) 2.84 (±0.46) 5.89 (±1.24) 0.005 n (%) n (%) χ2 OR (95% CI)
Females 103 (71) 42 (29) Males 100 (69) 45 (31) 0.15 0.80 0.91 (0.55-1.50)
Axial disease 46 (77) 14 (23 No axial disease 156 (68) 72 (32) 1.54 0.27 0.66 (0.34-1.28)
Dactylitis 34 (53) 30 (47) No dactylitis 155 (74) 53 (26) 10.6 0.002 2.58 (1.44-4.62)
Nail psoriasis 85 (71) 35 (29) No nail psoriasis 113 (69) 50 (31) 0.075 0.80 0.93 (0.56-1.56)
Deformed joints 89 (64) 49 (36) Not deformed joints 112 (75) 38 (25) 3.53 0.06 1.62 (0.98-2.69)
Psoriasis type 1 154 (70) 66 (30) Not psoriasis type 1 47 (69) 21 (31) 0.019 0.88 0.96 (0.53-1.73)
Mono-/oligoarthritis 84 (72) 33 (28) Polyarthritis 94 (71) 38 (29) 0.01 0.92 1.03 (0.59-1.79)
Five SNPs, in three different inflammasome genes, were investigated in Paper II,
two in NLRP1 (rs878329G/C, rs8079034C/T), two in NLRP3 (rs10733113 G/A,
rs35829419 C/A) and one in CARD8 (rs2043211A/T). All polymorphisms were
analysed for association with different clinical phenotypes of PsA, e.g. skin
psoriasis type1 (onset <40 years), axial disease with- or without peripheral
arthritis, mono-/oligoarthritic or polyarthritic disease phenotype, nail psoriasis,
destructive-/deforming disease phenotype (x-ray and/or clinical), measurable
inflammation (ESR >20 mm/h and/or CRP >10 mg/L) in active disease,
bDMARD ever, csDMARD ever, as defined in Table 5. Significant associations
were found with four different PsA disease phenotypes with four different SNPs
(Table 11);
The C-allele and the genotype CC (vs CG+GG) of NLRP1 rs878329 were
significantly associated with PsA patients with axial involvement of
disease, with or without peripheral joint involvement (χ2=4.45, OR
(95%CI); 1.37 (1.02-1.84), p=0.035 and χ2=5.82, OR (95%CI); 1.84 (1.12-
3.04), p=0.016 respectively) (Table 11). In a previous family study on
patients with Pso, an increased transmission of rs878329C to affected
37
family members was seen and homozygosity was associated with a
younger age of onset (Ekman, Verma et al. 2014). In this study, no
association was detected for this polymorphism with Pso type 1 (onset <
40 years).
Instead, an association with Pso type1 and the G-allele of NLRP3
rs10733113 (χ2=9.59, OR (95%CI); 1.76 (1.23-2.53), P=0.0020) was
found (Table 11). This polymorphism had previously been found over-
transmitted to individuals with a more widespread Pso in a family-based
study (Carlstrom, Ekman et al. 2012). Pso type1 is considered a specific
entity with higher degree of heritability and is generally considered to be
associated with a more severe Pso (Henseler and Christophers 1985,
Boehncke and Schon 2015). Thus, the results of this study strengthen the
putative role of this polymorphism for the severity of psoriasis skin
disease.
An association was identified between the major, C-allele of NLRP3-
Q705K rs35829419 (χ2=4.72, OR (95% CI); 1.63 (1.04-2.55), p=0.030)
and PsA patients with a destructive-/deforming disease phenotype that
could indicate a role in disease severity (Table 11).
The association with carriage of the T-allele of NLRP1 rs8079034 and
patients who, at any time, had been prescribed a csDMARD (χ2=9.59, OR
(95%CI); 1.76 (1.23-2.53), P=0.0020) (Table 11) is interesting. A similar
trend, although not reaching significance was seen for patients
prescribed a bDMARD (χ2=3.24, OR (95%CI); 1.48 (0.96-2.28),
P=0.072) (data not shown). Prescription of a DMARD can be considered
a surrogate marker for a more aggressive disease. Thus, the data from
this study could indicate an association with a more severe PsA disease
phenotype and this polymorphism.
So far, only one study has been published in which SNPs in genes related to the
inflammasome have been investigated in patients with PsA (Loft, Skov et al.
2018). In their study, two of the SNPs investigated in this study were analysed,
rs2043211 in CARD8 and rs878329 in NLRP1 and no significant associations with
PsA in comparison with population controls were detected. Thus, this study is the
first in which an association of polymorphisms in inflammasome genes and PsA
have been shown.
38
Table 11. Distribution of frequencies of genotypes and alleles of NLRP1
(rs878329 and rs8079034) and NLRP3 (rs35829419 and rs10733113) in different
phenotypes of PsA. All data presented as n (%). Only SNPs and phenotypes with
significant associations are shown.
Axial disease
Peripheral disease
OR (95%CI) χ2 p-value
NLRP1 rs878329
N=107 N=539
CC 26 (24) 80 (15) Ref. GC 51 (48) 275 (51) 0.57 (0.33-0.97) 4.31 0.038 GG 30 (28) 184 (34) 0.50 (0.28-
0.90) 5.41 0.020
CC (vs GC+GG) 26 (24) 80 (15) 1.84 (1.12-3.04) 5.82 0.016
C carriage 77 (72) 355 (66) 1.33 (0.84-2.10) 1.50 0.22 C allele 103 (48) 435(41) 1.37 (1.02-1.84) 4.45 0.035 csDMARD2
ever never csDMARD
NLRP1 rs8079034
N=499 N=216
TT 19 (4) 5 (2) Ref. CT 160 (32) 47 (22) 0.90 (0.32-2.53) 0.043 0.84
CC 320 (64) 164 (76) 0.51 (0.19-1.40) 1.75 0.19
CC (vs. CT+TT) 320 (64) 164 (76) 0.57 (0.39-0.81) 9.59 0.0020
T carriage 179 (36) 52 (24) 1.76 (1.23-2.53) 9.59 0.0020 T allele 198 (20) 57 (13) 1.63 (1.18-2.24) 9.09 0.0026 Pso-type 11 Not Pso-type 1 NLRP3 rs10733113
N=439 N=210
AA 5 (1) 8 (4) Ref. GA 87 (20) 53 (25) 2.63 (0.82-8.45) 2.78 0.095
GG 347 (79) 149 (71) 3.73 (1.20-11.58) 5.89 0.015 GG (vs. GA+AA) 347 (79) 149 (71) 1.54 (1.06- 2.25) 5.16 0.023 G carriage 434 (99) 202 (96) 3.44 (1.11-10.64) 5.16 0.023
G allele 781(89) 351(84) 1.58 (1.13-2.21) 7.38 0.007 Destructive
disease Non-destructive disease
NLRP3-Q705K rs35829419
N=314 N=360
AA 0 (0) 2 (0.3) - CA 32 (10) 54 (15) Ref. CC 282 (90) 304 (84) 1.56 (0.98-2.50) 3.59 0.058
CC (vs. CA+AA) 282 (90) 304 (84) 1.62 (1.02-2.58 4.25 0.039
C allele 596 (95) 662 (92) 1.63 (1.04-2.55) 4.72 0.030 1skin psoriasis with onset before 40 years 2csDMARDS= conventional synthetic disease modifying anti-rheumatic drug
39
In two recent publications from Spalinger et al., an interesting link between
PTPN22 and the NLRP3 inflammasome have been discovered. In their first study,
they discovered that NLRP3 activation is negatively regulated by tyrosine
phosphorylation and that PTPN22 is the phosphatase responsible for the
dephosphorylation and subsequent activation of NLRP3 (Spalinger, Kasper et al.
2016). In their second publication they present data indicating an involvement of
autophagosomes, where phosphorylated but not non-phosphorylated NLRP3
were found in autophagosomes (Spalinger, Lang et al. 2017). Thus, the
dephosphorylation of NLRP3 by PTPN22 protects the NLRP3 from
autophagosomes and lead to increased inflammasome activity, with a subsequent
increase in inflammatory mediators such as IL-1β and IL-18.
The PTPN22+1858T variant is thought to be a gain-of –function mutation, but
published data are conflicting (Vang, Congia et al. 2005). Considering the results
from Spalinger et al., an increased dephosphorylating activity of the mutated
PTPN22 (with a tryptophan in position 620) could lead to a higher NLRP3
inflammasome activity and increased inflammation. In conclusion, the data
linking PTPN22 and inflammasomes illustrate the great complexity in the
regulation of immune response and autoimmunity and strengthens the need for
further studies in the area.
Analysis of biomarkers (Paper III)
In this study, we decided to investigate biomarker expression in PsA in relation
to disease activity, disease phenotypes and in comparison with healthy controls.
A total of 39 biomarkers were analysed, IL-18, calprotectin (analysed with ELISA)
and 37 from the MSD®, V-plex, 40-plex kit® (Table 7). In addition to standard
statistical methods, OPLS-DA was used. OPLS is a modification of the partial
least squares method that has been used in chemometrics analysis, with similar
capacity as the original, but improved model interpretation (Trygg and Wold
2002, Eriksson, Rosen et al. 2012). With OPLS-DA it is possible to calculate
which variables contribute most to the difference between groups.
With OPLS-DA it was not possible to discriminate PsA from controls (Figure 4)
and no significant difference in individual biomarkers between patients and
controls was found using t-test. However, the relatively small number of controls
could lower the sensitivity and the results, therefore, should be interpreted with
caution.
40
Figure 4. Comparison of PsA patients and controls with OPLS-DA
In addition, with OPLS-DA no complete separation was visualised between PsA
disease phenotypes, but a visual trend was obvious, with individual biomarkers
differing significantly between the different phenotypes in t-tests (Figure 5,
Figure 6 and Table 12).
Variables reflecting disease activity at clinical examination
Significant associations with higher levels of CRP (pc=0.0008), IL-6 (pc =0.001),
IL-16 (pc =0.007), calprotectin (pc =0.014), IL-12/IL-23p40 (pc =0.02) and
ICAM-1 (pc =0.045) was detected in PsA patients, who, at clinical examination
and blood sample collection, presented with a moderate to high PsA disease
activity according to the investigating clinician (Figure 5, Table 12). These
associations indicate a linkage between these markers and disease activity.
Biomarkers in relation to PsA disease activity have previously been investigated
(Fink, Cauza et al. 2007, Madland, Larsen et al. 2007, Szodoray, Alex et al. 2007).
In the study by Szodoray et al. EGF, INF-α, VEGF, MIP-1α and IL-12p40
discriminated between both controls and subsets of PsA with different levels of
disease activity. Madland et al. found association between PsA disease activity
and calprotectin (Madland, Larsen et al. 2007) and in a small study by Fink et al.
higher levels of VEGF were associated with active PsA (Fink, Cauza et al. 2007).
Thus, our results confirm previously detected associations with calprotectin
(Madland, Larsen et al. 2007) and IL-12p40 (Szodoray, Alex et al. 2007), but did
41
not reveal any significant association with EGF, VEGF or MIP-1α. These
variations could be due to differences in study design, e.g., in the study by
Szodoray et al. PsA patients with a polyarthritic disease pattern were selected, the
ratio between PsA and controls differ and a different statistical method was used.
The study by Fink et al. is small and defines active PsA by the number of arthritic
joints. Consequently, direct comparison between the studies is difficult.
Figure 5. PsA patients with ≥ moderate disease activity compared with ≤ low
disease activity at clinical examination and collection of blood
Figure 1: Orthogonal partial least square analysis (OPLS) of PsA patients sub-grouped according to ≥
moderate disease activity and ≤ low disease activity. (a) Score scatter plot. (b) VIP (Variable
Importance for the Projection) plot showing degree of importance of the different biomarkers to the
model. Whiskers show the confidence interval of the importance value
42
Table 12. Biomarkers associated with different PsA disease characteristics.
Disease characteristic, n (%) Biomarker Concentration, mean (pg/ml) Pc-value
Variables at clinical examination
≥moderate ≤low
≥moderate disease activity1, 87 (32)
CRP 16.5 x 106 6.76 x 106 0.0008
vs. ≤low disease activity1, 185 (68) IL-6 2.35 1.24 0.001 IL-16 240 204 0.007 calprotectin 1.24 x 106 0.86 x 106 0.014 IL-12/IL-
23p40 157 121 0.02
ICAM-1 5.72 x 105 5.09 x 105 0.045 Overall disease characteristics
Polyarthritis Mono-/oligo arthritis
Polyarthritic disease pattern, 130 (52)
IL-6 2.13 1.02 0.0006
vs. mono-/oligo arthritis disease pattern, 123 (49)
SAA 13.0 x 106 5.41 x 106 0.009
CRP 13.1 x 106 5.62 x 106 0.012 IL-8 16.8 10.1 0.04 Axial Peripheral Axial disease with or without peripheral disease, 45 (17)
IL-6 2.20 1.44 0.044
vs. peripheral disease only, 220 (83)
IL-16 245 209 0.044
MIP-1β 108 95 0.039 Measurable
inflammation Not measurable inflammation
Measurable inflammation when clinically active PsA disease 126 (52)
CRP 15.5 x 106 4.16 x 106 0.0001
vs. not measurable inflammation when clinically active PsA disease 117 (48)
SAA 13.9 x 106 5.20 x 106 0.003
IL-6 2.10 1.12 0.003 VCAM 7.85 x 105 6.91 x 105 0.017 calprotectin 1.15 x 106 0.80 x 106 0.020 IL-17A 4.02 3.11 0.022 TNF-β 0.534 0.307 0.022 IL-16 225 198 0.025 IL-12/IL-
23p40 139 114 0.040
bDMARD ever Never bDMARD bDMARD2, ever 42 (16) vs. never bDMARD 221 (84)
TNF-β 0.864 0.338 0.0001
TNF-α 14.5 2.91 0.0003 calprotectin 1.76 x 106 0.885 x 106 0.0009 CRP 21.5 x 106 8.39 x 106 0.016 Tie-2 (lower
level) 3290 3530 0.027
1 upon clinical investigation and collection of blood. 2 etanercept, adalimumab, infliximab,
certolizumab, golilumab, abatacept, ustekinumab or infliximab
43
Dactylitis was also recorded, but only a few individuals (n=16) presented with
active dactylitis at investigation. In t-test analysis, patients with active dactylitis
at investigated had significantly higher levels of TNF-α (pc =0.012), but there was
no difference with Mann-Whitney U test. Of the 16 individuals, two individuals
had very high levels, contributing to the significance in t-test. Ongoing dactylitis
is a marker of a more severe disease phenotype associated with radiographic
progression and worse clinical outcome (Brockbank, Stein et al. 2005, Geijer,
Lindqvist et al. 2015, Mease, Karki et al. 2017), but due to small numbers, it is not
possible to draw conclusions from the current study. To investigate this further
a prospective study, preferably on patients with early PsA, is suggested.
Serological biomarkers in relation to disease phenotypes
We found significant associations with different clinical PsA disease phenotypes
and different serological biomarkers, e.g. mono-/oligoarthritic disease
phenotype compared with polyarthritis, PsA with or without axial disease, PsA
disease with measurable inflammation when clinically active PsA disease and PsA
with past or present treatment with bDMARD (Table 12 and Figure 6). No
association was found with a destructive/deforming disease phenotype.
In the sub-group of PsA patients who had, at any time, been prescribed bDMARD,
in the majority of cases TNF-inhibitors, increased levels of TNF-β (pc=0.0001),
TNF-α (pc=0.0003) calprotectin (pc=0.0009) and CRP (pc=0.016) were found.
Patients prescribed this treatment likely represents a more aggressive disease
phenotype. Most patients started with bDMARD after serum sampling (n=27),
only nine individuals were currently receiving bDMARD at the time of collection
of blood samples and in these cases, the concentration of TNF-α is dependent of
the relation to the last dose. Unfortunately, the relation between blood sampling
and the last dose was unknown. However, since TNF-inhibitors, would, most
likely reduce the concentration of TNF-α, the significant difference would not be
reduced. Thus, the higher levels of TNF-α, TFN-β, calprotectin and CRP, possibly
reflect a more aggressive disease phenotype with a need for biological treatment.
44
Figure 6. PsA patients with mono-/oligoarthritis compared with polyarthritis.
Figure 1: Orthogonal partial least square analysis (OPLS) of PsA patients sub-grouped according to ≥
moderate disease activity and ≤ low disease activity. (a) Score scatter plot. (b) VIP (Variable
Importance for the Projection) plot showing degree of importance of the different biomarkers to the
model. Whiskers show the confidence interval of the importance value.
In conclusion, in this study on well-characterized patients with PsA, interesting
associations with clinical disease phenotypes of PsA and biomarkers were
detected. The study highlights the heterogeneity of PsA disease, with different
biomarkers associated with different disease phenotypes and the association of
some biomarkers with PsA disease activity confirms the inflammatory nature of
PsA. The study confirms previous findings of PsA being a complex disease leading
to difficulties in setting diagnosis (Mease 2011, Coates and Helliwell 2017,
45
Marchesoni, De Marco et al. 2018), as none of the biomarkers analysed could,
neither by itself, nor in combination, separate PsA patients from healthy controls.
Perhaps different/new approaches for finding new and specific biomarkers for
PsA are needed. Recently, an interesting approach to find novel biomarkers to
differentiate PsA from Pso was used by Cretu and colleagues (Cretu, Gao et al.
2018), when novel protein markers previously found by a method using mass
spectrometry in synovial fluid and psoriasis plaque was used (Cretu, Prassas et
al. 2014, Cretu, Liang et al. 2015). In the study, serum samples from cases with
PsA, Pso and healthy controls were investigated. In their study CD5-like protein
(CD5L, also known as Apoptosis Inhibitor expressed by Macrophages, Integrin-
β5 (ITGβ5), Mac-2-binding protein (M2BP), Myeloperoxidase (MPO), MMP‐3,
and CRP levels were markers for PsA and the combination of ITGβ5, M2BP, and
CRP level differentiated PsA from cutaneous Pso, better than CRP level alone
(Cretu, Gao et al. 2018).
Biomarkers for RA and PsA with a focus on predictors for early joint damage were
reviewed recently by Mc Ardle (Mc Ardle, Flatley et al. 2015), and include a list of
candidate biomarkers for joint damage in RA and PsA. Considerably more
candidates were suggested for RA, but the list includes calprotectin, SAA, IL-1
and VEGF investigated in this thesis. In this study association with disease
activity and calprotectin was detected; SAA was associated with a polyarthritic
disease phenotype and measurable inflammatory activity when clinically active
PsA disease. In the review IL-6, IL-16 and CRP were suggested as being
candidates for joint damage in RA. In this study IL-6 and CRP were associated
with disease activity, polyarthritic disease phenotype and CRP with prescription
of bDMARD, IL-16 was associated with axial involvement and with measurable
inflammation when clinically active PsA disease.
Investigation of mortality, cause of death and incidence of
acute cardiovascular disease in patients with PsA compared
with the general population (Paper IV)
Mortality and cause of death
In this study, patients with PsA were compared with the general population of
Västerbotten County. An increased SMR was found in patients with PsA for death
due to disease(s) of the circulatory system (ICD 10; I00–I99) (SMR (95%CI); 1.64
(1.02-2.52), whilst no difference in SMR for overall mortality was seen (SMR
(95%CI); 1.22 (0.89-1.63). Causes of death are presented in Table 13 and Figure
7.
46
Table 13. Causes of death
Cause of death ICD codes
Female n (%)
Male n (%)
Female+Male n (%)
Overall 19 25 44
Circulatory system I00-I99 9 (47) 12 (48) 21 (48)
Malignant
neoplasms
C00-C97 6 (32) 8 (32) 14 (32)
Respiratory
system
J00-J99 0 1 (4) 1 (2)
Other causes 4 (21) 4 (16) 8 (18)
Figure 7. Causes of death in male and female PsA patients during the study
Factors associated with death in PsA patients
When traditional risk factors and putative PsA related risk factors were evaluated
in relation to death, patients who died were older, had a longer duration of skin
disease and had a higher mean disease activity index (DAI). In addition, a
significantly higher fraction of patients who died had used oral corticosteroids,
while a significantly reduced number had used NSAIDs. Also, among patients
who died a higher proportion had destructive-/deforming disease and a
significantly higher proportion had axial involvement (Table 14).
When all significant variables associated with death were included in a multiple
logistic regression model with backward elimination, predictors for death
47
remaining significant were DAI (OR 95% CI; 1.88 (1.30–2.72)) and axial
involvement (OR 95% CI 0.33 (0.15–0.74)), adjusted for age.
Table 14. Comparison of disease characteristics at the end of the study between
patients who died and those who were alive at the end of the study. Data are
presented as n (%) unless otherwise indicated.
Alive Dead p-value OR(95% CI)
Age, years ±SD (n) 58.4 ±13.0 (420) 70.4 ±13.7 (44) <0.001 1.08(1.05-1.11)
Duration PsA, years ±SD (n) 20.3 ±10.9 (419) 21.4 ±13.7 (44) 0.566 1.01(0.98-1.04)
Duration Pso, years ±SD (n) 29.9 ±14.9 (399) 37.9 ±19.3 (39) 0.002 1.03(1.01-1.05)
BMI kg/m2 ±SD (n) 27.7 ±5.2 (370) 27.2 ±4.7 (30) 0.636 0.98(0.91-1.06)
DAI mean ±SD (n) 3.87 ±0.82 (411) 4.49 ±1.13 (43) <0.001 1.94(1.43-2.64)
Male gender, n (%) 209 (50) 25 (57) 0.373 0.75(0.40-1.41)
Smoking (ever), n (%) 224 (54) 24 (60) 0.505 1.25(0.65-2.43)
Hypertension, n (%) 181 (43) 24 (55) 0.157 1.56(0.84-2.92)
Hyperlipidaemia, n (%) 66 (16) 5 (11) 0.435 0.68(0.26-1.79)
Diabetes, n (%) 49 (12) 9 (20) 0.099 1.93(0.87-4.25)
Destructive/deforming
disease, n (%)
204 (49) 29 (67) 0.021 2.16(1.11-4.21)
bDMARD (ever), n (%) 55 (13) 2 (4.5) 0.098 0.31(0.74-1.34)
csDMARD (ever), n (%) 285 (68) 27 (61) 0.383 0.75(0.40-1.43)
NSAID (ever), n (%) 303 (72) 24 (54) 0.014 0.46(0.24-0.86)
Oral corticosteroid
treatment (ever), n (%)
123 (29) 20 (46) 0.028 2.00(1.07-3.76)
Fulfilling Caspar-criteria,
n (%)
378 (90) 40 (91) 0.882 1.08(0.37-3.18)
Polyarthritis (according to
Moll and Wright), n (%)
173 (41) 24 (54) 0.088 1.71(0.92-3.20)
Dactylitis (ever), n (%) 119 (41) 10 (33) 0.421 0.72(0.33-1.60)
Nail-involvement (ever),
n (%)
162 (53) 16 (48) 0.640 0.84(0.41-1.73)
Axial involvement, n (%) 65 (15) 14 (32) 0.006 2.54(1.28-5.05)
Axial and peripheral joint
involvement, n (%)
35 (8.3) 11 (24) <0.001 3.65(1.70-7.86)
PsA=psoriatic arthritis, Pso=psoriasis, BMI=body mass index, DAI=disease activity index,
DMARD=disease modifying anti-rheumatic drug, NSAID=non steroidal anti inflammatory drug
Patients with axial involvement of disease were further sub-divided in axial
disease with- or without peripheral disease. In the cohort with both axial and
peripheral involvement a higher proportion died (27%) compared with patients
with only peripheral involvement of disease (7.2%) (OR (95%CI); 4.02 (1.84–
8.84), p < 0.001). No significant difference was seen when patients with axial
disease only were compared with patients with only peripheral disease (9.1% vs
7.2%, OR 1.28, 95% CI 0.37–4.48) (Figure 8). Thus, the association was
significant only in patients with involvement of both spine and joints possibly
indicating a higher disease burden and increased risk of death in these patients
that would be interesting to evaluate in future studies.
48
Figure 8. Proportion of PsA patients who died according to disease phenotype
Since age is an obvious cause of death, patients were also stratified into different
age groups. With stratification into three age groups (< 40 yrs, 40–74 yrs, and >
75 yrs), the impact of higher DAI on death remained in the age group 40-74 years
(n=352, p=0.001) and with stratification in four age groups (<40, 40-54, 55-69,
>70), in the group 55-69 years (n=190, p=0.005). In the group of patients < 40
years (n=36), only one death occurred, thus statistical calculation in this sub-
group was inapposite.
Cardiovascular Events
The incidence of acute cardiovascular events (CVE), defined as myocardial
infarction (MI) or ischemic stroke, was also investigated in relation to the general
population of Västerbotten. Unfortunately, it was not possible to use a diagnosis
of instable angina pectoris in the calculation of SIR due to a less specific definition
being used in the statistics for the general population. Twenty-nine patients with
PsA suffered an MI or stroke, with the MI being fatal in three cases. The SIR
(95%CI) for an MI or stroke was 0.60 (0.40-0.86). The association was only
shown to be significant in male patients.
Factors associated with CVE among PsA patients
Traditional risk factors together with any likely PsA related risk factors in relation
with a CVE (stroke, MI or unstable angina pectoris) were also investigated.
Patients with PsA who experienced an acute CVE, were significantly older, but
Different disease manifestations compared with peripheral disease
only
0
20
40
60
80
100
120
peripheral disease only
(n=359)
axial and perpheral
disease (n=46)
axial disease only
(n=33)
%
not dead (%)
dead (%)
*** ns
49
had a shorter PsA disease duration. In addition, significantly fewer had been
treated with NSAIDs and a significantly higher proportion of patients with an
event had hypertension, hyperlipidaemia and/or diabetes (Table 15).
When all variables significantly associated with a CVE, and gender, were analysed
in a multiple logistic regression model with backward elimination, predictors for
a CVE remaining significant were shorter PsA disease duration and less NSAID
treatment adjusted for age.
Table 15. Comparison of disease characteristics at the end of the study between
patients with or without event during the study. Data are presented as n (%)
unless otherwise indicated.
No Event Event p-value OR(95% CI)
Age, y± SD (n) 57.6 ±13.3 (430) 70.7 ±12.1(34) <0.001 1.08(1.05-1.11)
Duration PsA, y±SD (n) 19.9±10.9 (430) 14.0±13.5 (33) 0.004 0.94(0.90-0.98)
Duration Pso, y±SD (n) 29.5±15.0 (407) 31.2±21.5 (31) 0.565 1.01(0.98-1.03)
BMI, kg/m2±SD(n) 27.7±5.2 (273) 27.8±4.5 (27) 0.872 1.01(0.93-1.08)
DAI, mean ±SD (n) 3.90±0.85 (420) 4.24±1.02 (34) 0.030 1.47(1.04-2.08)
Male gender, n (%) 215 (50) 19 (56) 0.51 0.79(0.39-1.59)
Smoking (ever), n (%) 226 (54) 22 (67) 0.16 1.70(0.08-3.59)
Hypertension, n (%) 179 (42) 26 (76) <0.001 4.5(1.99-10.2)
Hyperlipidaemia n (%) 61 (14) 10 (29) 0.019 2.5(1.14-5.49)
Diabetes n (%) 49 (12) 9 (27) 0.008 2.89(1.27-6.58)
Destructive/deforming
disease, n (%)
216 (51) 17 (50) 0.94 0.97(0.48-1.96)
bDMARD (ever), n (%) 56 (13) 1 (2.9) 0.083 0.20(0.03-1.5)
csDMARD (ever), n (%) 288 (67) 24 (71) 0.67 1.18(0.55-2.54)
NSAID (ever), n (%) 314 (73) 13 (38) <0.001 0.23(0.11-0.47)
Oral corticosteroids
(ever), n (%)
128 (30) 15 (44) 0.083 1.86(0.91-3.77)
Fulfilling Caspar-criteria,
n (%)
387 (90) 31 (91) 0.86 1.12(0.33-3.83)
Polyarthritis (according
to Moll and Wright), n
(%)
180 (42) 17 (50) 0.36 1.39(0.69-2.79)
Dactylitis (ever), n (%) 119 (40) 10 (38) 0.85 0.92(0.41-2.11)
Nail-involvement (ever),
n (%)
168 (53) 10 (40) 0.20 0.58(0.25-1.34)
Axial involvement, n (%) 74 (17) 5 (15) 0.70 0.83(0.31-2.21)
Axial and peripheral joint
involvement, n (%)
41 (9.6) 5 (15) 0.33 1.63(0.60-4.44)
PsA=psoriatic arthritis, Pso=psoriasis, BMI=body mass index, DAI=disease activity index,
DMARD=disease modifying anti-rheumatic drug, NSAID=non steroidal anti inflammatory drug
50
In conclusion, our data showed increased mortality rates due to cardiovascular
diseases compared with the general population and among PsA patients, also an
association between death and disease activity that indicate an involvement of
inflammation.
Considering previous data, indicating a high prevalence of traditional risk factors
in Pso and PsA (e.g. hypertension, hyperlipidaemia, increased body mass index
and diabetes mellitus) and the indicated increased frequency of indirect markers
for CVD, such as sub-clinical atherosclerosis, increased arterial stiffness, an
increased risk of mortality and acute cardiovascular events compared with the
general population would be expected. However, data on mortality and
cardiovascular comorbidity are still conflicting;
In a recent population study from the UK, mortality and causes of death in RA
and PsA was investigated. In contrast with RA patients, where increased overall-
and cardiovascular mortality was found, neither overall- nor cardiovascular
mortality was increased in PsA patients (Ogdie, Maliha et al. 2017).
Our study indicate a small, but significant, increase in deaths due to diseases of
the circulatory system and death was associated with disease activity, indicating
an involvement of inflammation. Indeed, recent data support increased risk of
CVD in patients with PsA. For example, in a meta-analysis from 2017 (Polachek,
Touma et al. 2017), increased risk of CVD (including cardiovascular- and
cerebrovascular events and heart failure) with a pooled OR of 1.44 (1.22-1.96).
One of the studies included in the meta-analysis was a Swedish study published
2017, in which an increased risk of acute coronary syndrome, stroke and venous
thromboembolism was detected in patients with PsA (Bengtsson, Forsblad-d'Elia
et al. 2017). Also, in a Danish nation-wide population study a small, but
significant, increased risk for myocardial infarction in patients with PsA was
found that disappeared after age-stratification (Egeberg, Thyssen et al. 2017).
In the present study, no increase in CVE was detected in PsA patients. It is
possible that differences in study populations and methods of analysis result in
different findings. The highly heterogeneous pattern of PsA disease could also
contribute to the differences (Miller, Ellervik et al. 2013). If a whole population is
investigated, e.g. with registries, it is not possible to differentiate between
different disease phenotypes and the whole spectra of PsA disease from mild to
severe is included. If instead hospital based databases are used or cohorts from
rheumatology specialist clinics, studies more likely reflect PsA patients with a
more severe disease. It is also possible that in cohort studies, older patients and
patients with co-morbidities are not included.
51
Concluding remarks
The heterogeneity and complexity of PsA disease remains a challenge. In the
studies included in this thesis, different aspects on PsA disease have been
investigated. PsA patients have been compared with population controls and
different clinical disease phenotypes of PsA disease have been compared among
the PsA patients included. The majority of the disease characteristics were used
in all four studies, except for some variables (Table 5). In summary, some of the
different clinical features show association in more than one of the studies while
others do not (Table 16);
A destructive-/deforming disease phenotype was associated the major,
C-allele, of NLRP3-Q705K (rs35829419). A different definition was used
in Study I where the number of deformed joints was associated with
carriage of PTPN22+1858T.
Axial disease (with or without peripheral disease) was associated with the
C-allele and the CC genotype of NLRP1 rs878329 and with higher levels
of IL-6, IL-16 and MIP-1β. Axial disease was also associated with patients
who died in Study IV. In this study, this association was seen in the
combined phenotype with axial and peripheral disease (Figure 7).
A polyarthritic disease phenotype in comparison with mono-oligoartritic
disease phenotype was associated with higher levels of IL-6, SAA, CRP
and IL-8 in study II. In the other three studies no associations with these
phenotypes were detected.
Prescription of csDMARD was associated with NLRP1 rs8079034T in
Study II and in patients prescribed a bDMARD, higher levels of TNF-α,
TNF-β, calprotectin and CRP was detected. Patients prescribed a
csDMARD and/or bDMARD were not examined in Study I and no
associations were detected in Study IV.
Early onset of skin psoriasis (Pso type I) was investigated in Study I -III,
and an association was found with the G-allele of NLRP3 rs10733113,
while no associations were detected with PTPN22+1858C/T or any of the
biomarkers investigated in Study III.
Nail-disease was analysed in Study I-IV and no association with this
phenotype was detected in any of the studies.
52
Dactylitis (ever) was associated with PTPN22+1858T in study I, but no
significant association were detected with this phenotype in study II-IV.
Table 16. Summary of significant associations in study I-IV in relation to
different PsA phenotypes
Disease phenotype/s
Paper I Paper II Paper III Paper IV
Destructive-
/deforming disease
(II-IV) or number of deformed joints (I)
PTPN22+1858T
(carriage)
NLRP3-
Q705K
(rs35829419)
No associations No
associations
Measurable
inflammation when
clinically active PsA
disease (II-III) or disease activity index
(DAI) (IV)
Not analyzed No
associations
CRP, SAA, IL-6,
VCAM,
Calprotectin, IL-
17A, TNF-β, IL-16,
IL12IL23p40
Death
Dactylitis (ever) PTPN22+1858T
(carriage)
No
associations
No associations No
associations
Psoriasis type I No association NLRP3 rs10733113
(G-allele)
No associations Not analyzed
csDMARD (ever) Not analyzed NLRP1
rs8079034T
No associations No
associations
bDMARD (ever) Not analyzed No
associations
TNF-β,TNF-α,
Calprotectin, CRP,
Tie-2 (lower
level)
No
associations
PsA disease activity at clinical
investigation (III)
Not analyzed Not analyzed CRP, IL-6, IL-16, Calprotectin, IL-
12IL23p40,
ICAM-1
Not analyzed
Polyarthritis vs
mono-oligoarthritis (I-IV)
No associations No
associations
IL-6, SAA, CRP,
IL-8
No
associations
Axial involvement vs
peripheral disease
only (I-IV)
No associations NLRP1
rs878329 (C-
allele)
IL-6, IL-16,
MIP-1β
Death
Peripheral and axial disease vs peripheral
disease only (I-IV)
Not analyzed No associations
No associations Death
In comparison with controls from the general population, the PTPN22+1858T
and CARD8-C10X were associated with PsA patients and an increased SMR for
deaths in diseases of the circulatory system was detected for PsA patients. No
significant differences were found for any of the 39 biomarkers investigated in
study III for PsA patients compared with controls, although this result must be
interpreted with caution due to relatively few control subjects.
53
Conclusions
The main conclusions from this study on patients with psoriatic arthritis in a
population from northern Sweden can be summarized as follows:
The PTPN22+1858 C/T polymorphism was significantly associated with
PsA in comparison with controls. Among PsA patients, carriage of
PTPN22+1858T was associated with dactylitis and the number of
deformed joints.
The AA genotype of the inflammasome-related polymorphism CARD8-
C10X, was significantly associated with PsA patients compared with
controls, with the strongest association in patients with peripheral
disease without axial involvement.
Among PsA patients, different inflammasome related polymorphisms
were significantly associated with different PsA disease phenotypes; e.g.
the C-allele of NLRP1 rs878329 with axial involvement of disease, the G-
allele of NLRP3 rs10733113 with Pso type 1, the C-allele of NLRP3-Q705K
rs35829419 with a destructive-/deforming disease phenotype and the T-
allele of NLRP1 rs8079034 with patients prescribed a csDMARD.
A significant association with higher levels of CRP, IL-6, IL-16,
calprotectin, IL-12/IL-23p40 and ICAM-1 was detected among PsA
patients presenting with a moderate/high disease activity compared with
PsA patients with low /none disease activity.
Among PsA patients, different serological biomarkers were significantly
associated with different PsA disease phenotypes, e.g. IL-6, SAA, CRP
and IL-8 were associated with a polyarthritic disease phenotype; IL-6,
IL-16 and MIP-1β with axial disease with- or without peripheral disease;
CRP, SAA, IL-6, VCAM, Calprotectin, IL-17A, TNF-β , IL-16 and IL-
12/IL-23p40 with measurable inflammation when clinically active PsA
disease; TNF-β, TNF-α, calprotectin, CRP and Tie-2 with PsA patients
prescribed a bDMARD.
An increased SMR for death in diseases of the circulatory system was
detected in PsA patients in comparison with the general population.
Among PsA patients, significant predictors for death were disease activity
(DAI) and axial involvement.
54
Future perspectives
A correct, early diagnosis and prediction of disease severity in early stages of
disease are highly prioritised in the research agenda in PsA. As discussed, the
complexity and heterogeneity of PsA disease is substantial, e.g. in comparison
with RA. For example, an easy set of biomarkers as diagnostic aid and to monitor
disease activity would be of great value. In RA, although not positive in all cases,
RF and the highly specific ACPA are included in the diagnostic criteria. Recently,
a commercial blood test has been developed to monitor disease activity in RA with
a score calculated from concentrations of 12 serum biomarkers (VCAM-1, EGF,
IL-6, TNF-receptor type 1, MMP-1, MMP-3, cartilage glycoprotein 39 (YKL-40,
leptin, resistin, SAA, VEGF-A and CRP) (Eastman, Manning et al. 2012).
In the more heterogeneous PsA perhaps new strategies might be required? As
suggested by previous research and the results presented in this thesis, PsA
patients possibly need to be sub-categorized to develop diagnostic and prognostic
tools. The different phenotypes of skin disease possibly also needs consideration.
Thus, in the future, it would be highly beneficial if studies of patients with PsA
include all types of PsA, but that patients also are sub-grouped according to
different phenotypes, both for the skin and joint disease.
The associations with different inflammasome genes and PsA suggest a role of
inflammasomes in the disease. Different mutations of NLRP3 are causally
associated with rare auto-inflammatory conditions characterized by fever and
excessive IL-1 production. In this study an association was found between the
major, C-allele of NLRP3-Q705K and PsA patients with a destructive-/deforming
disease phenotype. The functional polymorphism at this site corresponds to a
transition from a glutamine (Q) to a lysine (K). This transition results in a “gain
of function” of the NLRP3-inflammasome leading to excessive IL-1β and IL-18
production (Verma, Sarndahl et al. 2012). Thus, the association with a
destructive-/deforming disease phenotype detected in this study is not to the
minor allele causing excessive IL-1β and IL-18 production.
In clinical practice, I have met patients with PsA describing fever as an associated
feature in conjunction with other signs of active PsA disease. Interestingly, a case
report on an HLA-B27 positive male patient presenting with fewer, arthritis of
large joints and elevated CRP-levels showed that the patient was heterozygous for
both NLRP3-Q705K and CARD8-C10X. The patient had elevated IL-1β levels and
responded well to the IL-1 blocking agent Anakinra (Verma, Lerm et al. 2008).
PsA patients are generally considered unresponsive to treatment with IL-1
blockers, but elevated levels of IL-1β has been found in psoriatic lesions (Buerger,
Richter et al. 2012). Considering the heterogeneity of PsA patients, it is possible
55
that the sub-group presenting with fever could respond to this treatment? It
would be interesting to analyse both the combination of CARD8-C10X and
NLRP3-Q705K polymophisms and the levels of IL-1β and IL-18 in this sub-group
of PsA patients in early/active disease.
In this study, a relatively large cohort of patients with PsA is included, but the
patients have been included over a long period and in different studies with a
specified focus. In the future, it would be interesting to investigate PsA patients
in both early and established disease, and in addition to the disease phenotypes
investigated in this thesis, also sub-categorize patients according to other joint
and skin phenotypes and to include anamnestic symptoms of fever and
gastrointestinal symptoms. It would also be interesting to analyse biomarkers in
blood samples, synovial fluid and synovial biopsies in both early/active disease
and after treatment, when the patients are in remission. Also important to
consider in future studies are the patient related outcomes such as pain, fatigue,
sleep and emotional well-being.
The studies presented in this thesis confirm the substantial heterogeneity of PsA
disease. In this thesis, no obvious pattern for any of the investigated disease
phenotypes was detected, but the results confirm the inflammatory nature of PsA
disease and some risk factors for a destructive disease phenotype were detected.
The results from these studies can be used as a ground for future studies in PsA.
56
Acknowledgements
So many people have contributed in different ways to make the production of this
thesis possible. In particular I want to thank;
Gerd-Marie Alenius, my supervisor, for endless patience and support! Thank you
for giving me the opportunity to work at the clinic and to be your PhD-student in
this interesting project! Without you this book would not have existed.
My co-supervisor, Solbritt Rantapää-Dahlqvist for always giving helpful
comments and advice. Your knowledge and expertise have been invaluable!
Martin Johansson, co-author, for help with the genetic analysis and statistical
calculations in Paper I.
Linda Johansson, co-author, for performing genetic analysis of controls and for
critical evaluation of Paper II.
Alf Kastbom and Peter Söderqvist for valuable advice in the planning of study II
and for genetic analysis of the patients in the same study.
Joakim Bygdell, NBIS (National Bioinformatics Infrastructure Sweden), for
performing the OPLS-DA and t-test analysis in Paper III.
Marie-Louise Öhman, for performing statistical analyses in Paper IV and Simon
Vallin for statistical advice in the same study.
Solveig Linghult, Maria Lindberg, Kristina Eriksson, Inger Bucht, Sonja Odeblom
and Viktoria von Zweigbergk for technical support.
Brian Ellis for valuable language checking and comments on my papers and
thesis.
The whole research group at Rheumatology for fruitful scientific discussions, for
example at journal club in the library. A special thanks to Mikael Brink for help
with construction of the new database and to Lisbeth Ärlestig who I have called
when things have been unclear, you know the answers!
All my dear colleagues and co-workers at the Department of Rheumatology for
your patience with my ups and downs during this project. Thank you for being
there and making me laugh, in both success and difficulties and for taking care of
my patients when I was away. You make our clinic a great place to work at!
57
All patients with Psoriatic Arthritis, who kindly participated in the studies,
donated blood and answered questionnaires.
My family, Peter, Alexander, André, Julia and Jacob for love and support. You are
the lights of my life! And thank you Peter, for your everlasting patience, for taking
care of all “ground service” during the production of this thesis and for letting me
leave piles of papers all over our apartment.
My parents, Ingrid and Gunnar, who taught me early in life to appreciate the joy
of learning, for always being supportive and believing in me and for your help
with the children when they were young and I wanted to work and study.
All my friends who I have neglected even though you mean so much to me. I hope
you have not forgotten me!
58
References
Abji, F., R. A. Pollock, K. Liang, V. Chandran and D. D. Gladman (2016). "Brief
Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic
Arthritis Among Patients With Psoriasis." Arthritis Rheumatol 68(12): 2911-
2916.
Ahlehoff, O., G. H. Gislason, M. Charlot, C. H. Jorgensen, J. Lindhardsen, J. B.
Olesen, S. Z. Abildstrom, L. Skov, C. Torp-Pedersen and P. R. Hansen (2011).
"Psoriasis is associated with clinically significant cardiovascular risk: a Danish
nationwide cohort study." J Intern Med 270(2): 147-157.
Alamanos, Y., P. V. Voulgari and A. A. Drosos (2008). "Incidence and prevalence
of psoriatic arthritis: a systematic review." J Rheumatol 35(7): 1354-1358.
Alenius, G. M., E. Berglin and S. Rantapaa Dahlqvist (2006). "Antibodies against
cyclic citrullinated peptide (CCP) in psoriatic patients with or without joint
inflammation." Ann Rheum Dis 65(3): 398-400.
Alenius, G. M., C. Eriksson and S. Rantapaa Dahlqvist (2009). "Interleukin-6 and
soluble interleukin-2 receptor alpha-markers of inflammation in patients with
psoriatic arthritis?" Clin Exp Rheumatol 27(1): 120-123.
Alenius, G. M., C. Friberg, S. Nilsson, J. Wahlstrom, S. R. Dahlqvist and L.
Samuelsson (2004). "Analysis of 6 genetic loci for disease susceptibility in
psoriatic arthritis." J Rheumatol 31(11): 2230-2235.
Alenius, G. M., E. Jidell, L. Nordmark and S. Rantapaa Dahlqvist (2002).
"Disease manifestations and HLA antigens in psoriatic arthritis in northern
Sweden." Clin Rheumatol 21(5): 357-362.
Alenius, G. M., B. G. Stegmayr and S. R. Dahlqvist (2001). "Renal abnormalities
in a population of patients with psoriatic arthritis." Scand J Rheumatol 30(5):
271-274.
Alenius, G. M., B. Stenberg, H. Stenlund, M. Lundblad and S. R. Dahlqvist
(2002). "Inflammatory joint manifestations are prevalent in psoriasis: prevalence
study of joint and axial involvement in psoriatic patients, and evaluation of a
psoriatic and arthritic questionnaire." J Rheumatol 29(12): 2577-2582.
Alinaghi, F., M. Calov, L. E. Kristensen, D. D. Gladman, L. C. Coates, D. Jullien,
A. B. Gottlieb, P. Gisondi, J. J. Wu, J. P. Thyssen and A. Egeberg (2018).
59
"Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review
and meta-analysis of observational and clinical studies." J Am Acad Dermatol.
Apel, M., S. Uebe, J. Bowes, E. Giardina, E. Korendowych, K. Juneblad, F.
Pasutto, A. B. Ekici, R. McManus, P. Ho, I. N. Bruce, A. W. Ryan, F. Behrens, B.
Bohm, H. Traupe, J. Lohmann, C. Gieger, H. E. Wichmann, L. Padyukov, O.
Fitzgerald, G. M. Alenius, N. J. McHugh, G. Novelli, H. Burkhardt, A. Barton, A.
Reis and U. Huffmeier (2013). "Variants in RUNX3 contribute to susceptibility to
psoriatic arthritis, exhibiting further common ground with ankylosing
spondylitis." Arthritis Rheum 65(5): 1224-1231.
Artis, D. and H. Spits (2015). "The biology of innate lymphoid cells." Nature
517(7534): 293-301.
Attaf, M., M. Legut, D. K. Cole and A. K. Sewell (2015). "The T cell antigen
receptor: the Swiss army knife of the immune system." Clin Exp Immunol 181(1):
1-18.
Avina-Zubieta, J. A., J. Thomas, M. Sadatsafavi, A. J. Lehman and D. Lacaille
(2012). "Risk of incident cardiovascular events in patients with rheumatoid
arthritis: a meta-analysis of observational studies." Ann Rheum Dis 71(9): 1524-
1529.
Baecklund, E., C. Sundstrom, A. Ekbom, A. I. Catrina, P. Biberfeld, N. Feltelius
and L. Klareskog (2003). "Lymphoma subtypes in patients with rheumatoid
arthritis: increased proportion of diffuse large B cell lymphoma." Arthritis Rheum
48(6): 1543-1550.
Bagnall, R. D., R. G. Roberts, M. M. Mirza, T. Torigoe, N. J. Prescott and C. G.
Mathew (2008). "Novel isoforms of the CARD8 (TUCAN) gene evade a nonsense
mutation." Eur J Hum Genet 16(5): 619-625.
Bai, Y., S. Nie, G. Jiang, Y. Zhou, M. Zhou, Y. Zhao, S. Li, F. Wang, Q. Lv, Y.
Huang, Q. Yang, Q. Li, Y. Li, Y. Xia, Y. Liu, J. Liu, J. Qian, B. Li, G. Wu, Y. Wu, B.
Wang, X. Cheng, Y. Yang, T. Ke, H. Li, X. Ren, X. Ma, Y. Liao, C. Xu, X. Tu and Q.
K. Wang (2014). "Regulation of CARD8 expression by ANRIL and association of
CARD8 single nucleotide polymorphism rs2043211 (p.C10X) with ischemic
stroke." Stroke 45(2): 383-388.
Begovich, A. B., V. E. Carlton, L. A. Honigberg, S. J. Schrodi, A. P. Chokkalingam,
H. C. Alexander, K. G. Ardlie, Q. Huang, A. M. Smith, J. M. Spoerke, M. T. Conn,
M. Chang, S. Y. Chang, R. K. Saiki, J. J. Catanese, D. U. Leong, V. E. Garcia, L. B.
McAllister, D. A. Jeffery, A. T. Lee, F. Batliwalla, E. Remmers, L. A. Criswell, M.
60
F. Seldin, D. L. Kastner, C. I. Amos, J. J. Sninsky and P. K. Gregersen (2004). "A
missense single-nucleotide polymorphism in a gene encoding a protein tyrosine
phosphatase (PTPN22) is associated with rheumatoid arthritis." Am J Hum
Genet 75(2): 330-337.
Bengtsson, C., M. L. Ohman, O. Nived and S. Rantapaa Dahlqvist (2012).
"Cardiovascular event in systemic lupus erythematosus in northern Sweden:
incidence and predictors in a 7-year follow-up study." Lupus 21(4): 452-459.
Bengtsson, K., H. Forsblad-d'Elia, E. Lie, E. Klingberg, M. Dehlin, S. Exarchou,
U. Lindstrom, J. Askling and L. T. H. Jacobsson (2017). "Are ankylosing
spondylitis, psoriatic arthritis and undifferentiated spondyloarthritis associated
with an increased risk of cardiovascular events? A prospective nationwide
population-based cohort study." Arthritis Res Ther 19(1): 102.
Bluett, J. and A. Barton (2012). "What have genome-wide studies told us about
psoriatic arthritis?" Curr Rheumatol Rep 14(4): 364-368.
Boehncke, W. H. and S. Boehncke (2012). "Cardiovascular mortality in psoriasis
and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic
implications, and perspectives." Curr Rheumatol Rep 14(4): 343-348.
Boehncke, W. H. and M. P. Schon (2015). "Psoriasis." Lancet 386(9997): 983-
994.
Bottini, N., L. Musumeci, A. Alonso, S. Rahmouni, K. Nika, M. Rostamkhani, J.
MacMurray, G. F. Meloni, P. Lucarelli, M. Pellecchia, G. S. Eisenbarth, D.
Comings and T. Mustelin (2004). "A functional variant of lymphoid tyrosine
phosphatase is associated with type I diabetes." Nat Genet 36(4): 337-338.
Bottini, N. and E. J. Peterson (2014). "Tyrosine phosphatase PTPN22:
multifunctional regulator of immune signaling, development, and disease." Annu
Rev Immunol 32: 83-119.
Bottini, N., T. Vang, F. Cucca and T. Mustelin (2006). "Role of PTPN22 in type 1
diabetes and other autoimmune diseases." Semin Immunol 18(4): 207-213.
Bowes, J., S. Loehr, A. Budu-Aggrey, S. Uebe, I. N. Bruce, M. Feletar, H. Marzo-
Ortega, P. Helliwell, A. W. Ryan, D. Kane, E. Korendowych, G. M. Alenius, E.
Giardina, J. Packham, R. McManus, O. FitzGerald, M. A. Brown, F. Behrens, H.
Burkhardt, N. McHugh, U. Huffmeier, P. Ho, A. Reis and A. Barton (2015).
"PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis:
61
evidence for a further PsA-specific risk locus." Ann Rheum Dis 74(10): 1882-
1885.
Braun, J., M. A. Khan and J. Sieper (2000). "Enthesitis and ankylosis in
spondyloarthropathy: what is the target of the immune response?" Ann Rheum
Dis 59(12): 985-994.
Brockbank, J. E., M. Stein, C. T. Schentag and D. D. Gladman (2005). "Dactylitis
in psoriatic arthritis: a marker for disease severity?" Ann Rheum Dis 64(2): 188-
190.
Buckley, C., C. Cavill, G. Taylor, H. Kay, N. Waldron, E. Korendowych and N.
McHugh (2010). "Mortality in psoriatic arthritis - a single-center study from the
UK." J Rheumatol 37(10): 2141-2144.
Buerger, C., B. Richter, K. Woth, R. Salgo, B. Malisiewicz, S. Diehl, K. Hardt, S.
Boehncke and W. H. Boehncke (2012). "Interleukin-1beta interferes with
epidermal homeostasis through induction of insulin resistance: implications for
psoriasis pathogenesis." J Invest Dermatol 132(9): 2206-2214.
Butt, C., L. Peddle, C. Greenwood, S. Hamilton, D. Gladman and P. Rahman
(2006). "Association of functional variants of PTPN22 and tp53 in psoriatic
arthritis: a case-control study." Arthritis Res Ther 8(1): R27.
Cargill, M., S. J. Schrodi, M. Chang, V. E. Garcia, R. Brandon, K. P. Callis, N.
Matsunami, K. G. Ardlie, D. Civello, J. J. Catanese, D. U. Leong, J. M. Panko, L.
B. McAllister, C. B. Hansen, J. Papenfuss, S. M. Prescott, T. J. White, M. F.
Leppert, G. G. Krueger and A. B. Begovich (2007). "A large-scale genetic
association study confirms IL12B and leads to the identification of IL23R as
psoriasis-risk genes." Am J Hum Genet 80(2): 273-290.
Carlstrom, M., A. K. Ekman, S. Petersson, P. Soderkvist and C. Enerback (2012).
"Genetic support for the role of the NLRP3 inflammasome in psoriasis
susceptibility." Exp Dermatol 21(12): 932-937.
Chandran, V. (2013). "The genetics of psoriasis and psoriatic arthritis." Clin Rev
Allergy Immunol 44(2): 149-156.
Chandran, V., R. J. Cook, J. Edwin, H. Shen, F. J. Pellett, S. Shanmugarajah, C.
F. Rosen and D. D. Gladman (2010). "Soluble biomarkers differentiate patients
with psoriatic arthritis from those with psoriasis without arthritis."
Rheumatology (Oxford) 49(7): 1399-1405.
62
Chandran, V., H. Shen, R. A. Pollock, F. J. Pellett, A. Carty, R. J. Cook and D. D.
Gladman (2013). "Soluble biomarkers associated with response to treatment with
tumor necrosis factor inhibitors in psoriatic arthritis." J Rheumatol 40(6): 866-
871.
Ciccia, F., G. Guggino, A. Ferrante, P. Cipriani, R. Giacomelli and G. Triolo (2016).
"Interleukin-9 and T helper type 9 cells in rheumatic diseases." Clin Exp Immunol
185(2): 125-132.
Ciccia, F., G. Guggino, A. Ferrante, S. Raimondo, R. Bignone, V. Rodolico, S.
Peralta, M. Van Tok, A. Cannizzaro, C. Schinocca, P. Ruscitti, P. Cipriani, R.
Giacomelli, R. Alessandro, F. Dieli, A. Rizzo, D. Baeten and G. Triolo (2016).
"Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed
Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic
Arthritis." Arthritis Rheumatol 68(8): 1922-1931.
Coates, L. C., O. FitzGerald, P. S. Helliwell and C. Paul (2016). "Psoriasis,
psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?"
Semin Arthritis Rheum 46(3): 291-304.
Coates, L. C., J. Fransen and P. S. Helliwell (2010). "Defining minimal disease
activity in psoriatic arthritis: a proposed objective target for treatment." Ann
Rheum Dis 69(1): 48-53.
Coates, L. C. and P. S. Helliwell (2016). "Defining Low Disease Activity States in
Psoriatic Arthritis using Novel Composite Disease Instruments." J Rheumatol
43(2): 371-375.
Coates, L. C. and P. S. Helliwell (2017). "Psoriatic arthritis: state of the art review."
Clin Med (Lond) 17(1): 65-70.
Coates, L. C., A. Kavanaugh, P. J. Mease, E. R. Soriano, M. Laura Acosta-Felquer,
A. W. Armstrong, W. Bautista-Molano, W. H. Boehncke, W. Campbell, A. Cauli,
L. R. Espinoza, O. FitzGerald, D. D. Gladman, A. Gottlieb, P. S. Helliwell, M. E.
Husni, T. J. Love, E. Lubrano, N. McHugh, P. Nash, A. Ogdie, A. M. Orbai, A.
Parkinson, D. O'Sullivan, C. F. Rosen, S. Schwartzman, E. L. Siegel, S. Toloza, W.
Tuong and C. T. Ritchlin (2016). "Group for Research and Assessment of Psoriasis
and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic
Arthritis." Arthritis Rheumatol 68(5): 1060-1071.
Cohen, M. R., D. J. Reda and D. O. Clegg (1999). "Baseline relationships between
psoriasis and psoriatic arthritis: analysis of 221 patients with active psoriatic
63
arthritis. Department of Veterans Affairs Cooperative Study Group on
Seronegative Spondyloarthropathies." J Rheumatol 26(8): 1752-1756.
Coulton, B. L., K. Thomson, D. P. Symmons and A. J. Popert (1989). "Outcome in
patients hospitalised for psoriatic arthritis." Clin Rheumatol 8(2): 261-265.
Cretu, D., L. Gao, K. Liang, A. Soosaipillai, E. P. Diamandis and V. Chandran
(2018). "Differentiating Psoriatic Arthritis From Psoriasis Without Psoriatic
Arthritis Using Novel Serum Biomarkers." Arthritis Care Res (Hoboken) 70(3):
454-461.
Cretu, D., K. Liang, P. Saraon, I. Batruch, E. P. Diamandis and V. Chandran
(2015). "Quantitative tandem mass-spectrometry of skin tissue reveals putative
psoriatic arthritis biomarkers." Clin Proteomics 12(1): 1.
Cretu, D., I. Prassas, P. Saraon, I. Batruch, R. Gandhi, E. P. Diamandis and V.
Chandran (2014). "Identification of psoriatic arthritis mediators in synovial fluid
by quantitative mass spectrometry." Clin Proteomics 11(1): 27.
de Vlam, K., A. B. Gottlieb and P. J. Mease (2014). "Current concepts in psoriatic
arthritis: pathogenesis and management." Acta Derm Venereol 94(6): 627-634.
Diani, M., G. Altomare and E. Reali (2015). "T cell responses in psoriasis and
psoriatic arthritis." Autoimmun Rev 14(4): 286-292.
Dougados, M., S. van der Linden, R. Juhlin, B. Huitfeldt, B. Amor, A. Calin, A.
Cats, B. Dijkmans, I. Olivieri, G. Pasero and et al. (1991). "The European
Spondylarthropathy Study Group preliminary criteria for the classification of
spondylarthropathy." Arthritis Rheum 34(10): 1218-1227.
Eastman, P. S., W. C. Manning, F. Qureshi, D. Haney, G. Cavet, C. Alexander and
L. K. Hesterberg (2012). "Characterization of a multiplex, 12-biomarker test for
rheumatoid arthritis." J Pharm Biomed Anal 70: 415-424.
Eberl, G., M. Colonna, J. P. Di Santo and A. N. McKenzie (2015). "Innate
lymphoid cells. Innate lymphoid cells: a new paradigm in immunology." Science
348(6237): aaa6566.
Eder, L., A. Haddad, C. F. Rosen, K. A. Lee, V. Chandran, R. Cook and D. D.
Gladman (2016). "The Incidence and Risk Factors for Psoriatic Arthritis in
Patients With Psoriasis: A Prospective Cohort Study." Arthritis Rheumatol 68(4):
915-923.
64
Eder, L., A. Polachek, C. F. Rosen, V. Chandran, R. Cook and D. D. Gladman
(2017). "The Development of Psoriatic Arthritis in Patients With Psoriasis Is
Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective
Cohort Study." Arthritis Rheumatol 69(3): 622-629.
Eder, L., Y. Wu, V. Chandran, R. Cook and D. D. Gladman (2016). "Incidence and
predictors for cardiovascular events in patients with psoriatic arthritis." Ann
Rheum Dis 75(9): 1680-1686.
Egeberg, A., L. E. Kristensen, J. P. Thyssen, G. H. Gislason, A. B. Gottlieb, L. C.
Coates, D. Jullien, P. Gisondi, D. D. Gladman, L. Skov and L. Mallbris (2017).
"Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide
register linkage study." Ann Rheum Dis 76(9): 1591-1597.
Egeberg, A., L. Mallbris, G. Hilmar Gislason, L. Skov and P. Riis Hansen (2015).
"Increased risk of migraine in patients with psoriasis: A Danish nationwide
cohort study." J Am Acad Dermatol 73(5): 829-835.
Egeberg, A., J. P. Thyssen, P. Jensen, G. H. Gislason and L. Skov (2017). "Risk of
Myocardial Infarction in Patients with Psoriasis and Psoriatic Arthritis: A
Nationwide Cohort Study." Acta Derm Venereol 97(7): 819-824.
Ekman, A. K., D. Verma, M. Fredrikson, C. Bivik and C. Enerback (2014).
"Genetic variations of NLRP1: susceptibility in psoriasis." Br J Dermatol 171(6):
1517-1520.
Elkayam, O., I. Yaron, I. Shirazi, M. Yaron and D. Caspi (2000). "Serum levels of
IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis." Rheumatol
Int 19(3): 101-105.
Eriksson, L., J. Rosen, E. Johansson and J. Trygg (2012). "Orthogonal PLS
(OPLS) Modeling for Improved Analysis and Interpretation in Drug Design." Mol
Inform 31(6-7): 414-419.
Espinoza, L. R., F. B. Vasey, C. G. Espinoza, T. S. Bocanegra and B. F. Germain
(1982). "Vascular changes in psoriatic synovium. A light and electron microscopic
study." Arthritis Rheum 25(6): 677-684.
Fearon, U., K. Griosios, A. Fraser, R. Reece, P. Emery, P. F. Jones and D. J. Veale
(2003). "Angiopoietins, growth factors, and vascular morphology in early
arthritis." J Rheumatol 30(2): 260-268.
65
Filer, C., P. Ho, R. L. Smith, C. Griffiths, H. S. Young, J. Worthington, I. N. Bruce
and A. Barton (2008). "Investigation of association of the IL12B and IL23R genes
with psoriatic arthritis." Arthritis Rheum 58(12): 3705-3709.
Fink, A. M., E. Cauza, W. Hassfeld, A. Dunky, P. M. Bayer, W. Jurecka and A.
Steiner (2007). "Vascular endothelial growth factor in patients with psoriatic
arthritis." Clin Exp Rheumatol 25(2): 305-308.
Fitzgerald, O. and V. Chandran (2012). "Update on biomarkers in psoriatic
arthritis: a report from the GRAPPA 2010 annual meeting." J Rheumatol 39(2):
427-430.
Fontenot, J. D., M. A. Gavin and A. Y. Rudensky (2003). "Foxp3 programs the
development and function of CD4+CD25+ regulatory T cells." Nat Immunol 4(4):
330-336.
Geijer, M., U. Lindqvist, T. Husmark, G. M. Alenius, P. T. Larsson, A. Teleman
and E. Theander (2015). "The Swedish Early Psoriatic Arthritis Registry 5-year
Followup: Substantial Radiographic Progression Mainly in Men with High
Disease Activity and Development of Dactylitis." J Rheumatol 42(11): 2110-2117.
Gelfand, J. M., D. D. Gladman, P. J. Mease, N. Smith, D. J. Margolis, T. Nijsten,
R. S. Stern, S. R. Feldman and T. Rolstad (2005). "Epidemiology of psoriatic
arthritis in the population of the United States." J Am Acad Dermatol 53(4): 573.
Gisondi, P., A. C. Fostini, I. Fossa, G. Girolomoni and G. Targher (2018).
"Psoriasis and the metabolic syndrome." Clin Dermatol 36(1): 21-28.
Gladman, D. D. (1994). "Natural history of psoriatic arthritis." Baillieres Clin
Rheumatol 8(2): 379-394.
Gladman, D. D. (2008). "Mortality in psoriatic arthritis." Clin Exp Rheumatol
26(5 Suppl 51): S62-65.
Gladman, D. D., M. Ang, L. Su, B. D. Tom, C. T. Schentag and V. T. Farewell
(2009). "Cardiovascular morbidity in psoriatic arthritis." Ann Rheum Dis 68(7):
1131-1135.
Gladman, D. D. and V. Chandran (2011). "Observational cohort studies: lessons
learnt from the University of Toronto Psoriatic Arthritis Program."
Rheumatology (Oxford) 50(1): 25-31.
66
Gladman, D. D., V. T. Farewell and C. Nadeau (1995). "Clinical indicators of
progression in psoriatic arthritis: multivariate relative risk model." J Rheumatol
22(4): 675-679.
Gladman, D. D., V. T. Farewell, K. Wong and J. Husted (1998). "Mortality studies
in psoriatic arthritis: results from a single outpatient center. II. Prognostic
indicators for death." Arthritis Rheum 41(6): 1103-1110.
Gladman, D. D., R. Shuckett, M. L. Russell, J. C. Thorne and R. K. Schachter
(1987). "Psoriatic arthritis (PSA)--an analysis of 220 patients." Q J Med 62(238):
127-141.
Goldbach-Mansky, R., N. J. Dailey, S. W. Canna, A. Gelabert, J. Jones, B. I. Rubin,
H. J. Kim, C. Brewer, C. Zalewski, E. Wiggs, S. Hill, M. L. Turner, B. I. Karp, I.
Aksentijevich, F. Pucino, S. R. Penzak, M. H. Haverkamp, L. Stein, B. S. Adams,
T. L. Moore, R. C. Fuhlbrigge, B. Shaham, J. N. Jarvis, K. O'Neil, R. K. Vehe, L. O.
Beitz, G. Gardner, W. P. Hannan, R. W. Warren, W. Horn, J. L. Cole, S. M. Paul,
P. N. Hawkins, T. H. Pham, C. Snyder, R. A. Wesley, S. C. Hoffmann, S. M.
Holland, J. A. Butman and D. L. Kastner (2006). "Neonatal-onset multisystem
inflammatory disease responsive to interleukin-1beta inhibition." N Engl J Med
355(6): 581-592.
Gossec, L., L. C. Coates, M. de Wit, A. Kavanaugh, S. Ramiro, P. J. Mease, C. T.
Ritchlin, D. van der Heijde and J. S. Smolen (2016). "Management of psoriatic
arthritis in 2016: a comparison of EULAR and GRAPPA recommendations." Nat
Rev Rheumatol 12(12): 743-750.
Gossec, L., J. S. Smolen, S. Ramiro, M. de Wit, M. Cutolo, M. Dougados, P. Emery,
R. Landewe, S. Oliver, D. Aletaha, N. Betteridge, J. Braun, G. Burmester, J. D.
Canete, N. Damjanov, O. FitzGerald, E. Haglund, P. Helliwell, T. K. Kvien, R.
Lories, T. Luger, M. Maccarone, H. Marzo-Ortega, D. McGonagle, I. B. McInnes,
I. Olivieri, K. Pavelka, G. Schett, J. Sieper, F. van den Bosch, D. J. Veale, J.
Wollenhaupt, A. Zink and D. van der Heijde (2016). "European League Against
Rheumatism (EULAR) recommendations for the management of psoriatic
arthritis with pharmacological therapies: 2015 update." Ann Rheum Dis 75(3):
499-510.
Gregersen, P. K., H. S. Lee, F. Batliwalla and A. B. Begovich (2006). "PTPN22:
setting thresholds for autoimmunity." Semin Immunol 18(4): 214-223.
Hansson, C., C. Eriksson and G. M. Alenius (2014). "S-calprotectin
(S100A8/S100A9): a potential marker of inflammation in patients with psoriatic
arthritis." J Immunol Res 2014: 696415.
67
Hansson, G. K., A. K. Robertson and C. Soderberg-Naucler (2006).
"Inflammation and atherosclerosis." Annu Rev Pathol 1: 297-329.
Haque, N., R. J. Lories and K. de Vlam (2016). "Comorbidities Associated with
Psoriatic Arthritis Compared with Non-psoriatic Spondyloarthritis: A Cross-
sectional Study." J Rheumatol 43(2): 376-382.
Haroon, M., P. Gallagher and O. FitzGerald (2015). "Diagnostic delay of more
than 6 months contributes to poor radiographic and functional outcome in
psoriatic arthritis." Ann Rheum Dis 74(6): 1045-1050.
Haroon, M., P. Gallagher, E. Heffernan and O. FitzGerald (2014). "High
prevalence of metabolic syndrome and of insulin resistance in psoriatic arthritis
is associated with the severity of underlying disease." J Rheumatol 41(7): 1357-
1365.
Harrington, L. E., R. D. Hatton, P. R. Mangan, H. Turner, T. L. Murphy, K. M.
Murphy and C. T. Weaver (2005). "Interleukin 17-producing CD4+ effector T
cells develop via a lineage distinct from the T helper type 1 and 2 lineages." Nat
Immunol 6(11): 1123-1132.
Harris, N. L. and F. Ronchese (1999). "The role of B7 costimulation in T-cell
immunity." Immunol Cell Biol 77(4): 304-311.
Hawkins, P. N., H. J. Lachmann and M. F. McDermott (2003). "Interleukin-1-
receptor antagonist in the Muckle-Wells syndrome." N Engl J Med 348(25):
2583-2584.
Hedrich, C. M. (2016). "Shaping the spectrum - From autoinflammation to
autoimmunity." Clin Immunol 165: 21-28.
Helliwell, P. S. (2009). "Established psoriatic arthritis: clinical aspects." J
Rheumatol Suppl 83: 21-23.
Henseler, T. and E. Christophers (1985). "Psoriasis of early and late onset:
characterization of two types of psoriasis vulgaris." J Am Acad Dermatol 13(3):
450-456.
Hinks, A., A. Barton, S. John, I. Bruce, C. Hawkins, C. E. Griffiths, R. Donn, W.
Thomson, A. Silman and J. Worthington (2005). "Association between the
PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK
population: further support that PTPN22 is an autoimmunity gene." Arthritis
Rheum 52(6): 1694-1699.
68
Hoffman, H. M., J. L. Mueller, D. H. Broide, A. A. Wanderer and R. D. Kolodner
(2001). "Mutation of a new gene encoding a putative pyrin-like protein causes
familial cold autoinflammatory syndrome and Muckle-Wells syndrome." Nat
Genet 29(3): 301-305.
Horreau, C., C. Pouplard, E. Brenaut, T. Barnetche, L. Misery, B. Cribier, D.
Jullien, S. Aractingi, F. Aubin, P. Joly, M. Le Maitre, J. P. Ortonne, C. Paul and
M. A. Richard (2013). "Cardiovascular morbidity and mortality in psoriasis and
psoriatic arthritis: a systematic literature review." J Eur Acad Dermatol Venereol
27 Suppl 3: 12-29.
Huffmeier, U., A. Reis, M. Steffens, J. Lascorz, B. Bohm, J. Lohmann, J. Wendler,
H. Traupe, W. Kuster, T. F. Wienker and H. Burkhardt (2006). "Male restricted
genetic association of variant R620W in PTPN22 with psoriatic arthritis." J
Invest Dermatol 126(4): 932-935.
Huffmeier, U., S. Uebe, A. B. Ekici, J. Bowes, E. Giardina, E. Korendowych, K.
Juneblad, M. Apel, R. McManus, P. Ho, I. N. Bruce, A. W. Ryan, F. Behrens, J.
Lascorz, B. Bohm, H. Traupe, J. Lohmann, C. Gieger, H. E. Wichmann, C. Herold,
M. Steffens, L. Klareskog, T. F. Wienker, O. Fitzgerald, G. M. Alenius, N. J.
McHugh, G. Novelli, H. Burkhardt, A. Barton and A. Reis (2010). "Common
variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and
psoriasis." Nat Genet 42(11): 996-999.
Husni, M. E., J. F. Merola and S. Davin (2017). "The psychosocial burden of
psoriatic arthritis." Semin Arthritis Rheum 47(3): 351-360.
Jamnitski, A., D. Symmons, M. J. Peters, N. Sattar, I. McInnes and M. T.
Nurmohamed (2013). "Cardiovascular comorbidities in patients with psoriatic
arthritis: a systematic review." Ann Rheum Dis 72(2): 211-216.
Jin, Y., C. M. Mailloux, K. Gowan, S. L. Riccardi, G. LaBerge, D. C. Bennett, P. R.
Fain and R. A. Spritz (2007). "NALP1 in vitiligo-associated multiple autoimmune
disease." N Engl J Med 356(12): 1216-1225.
Johansson, M., L. Arlestig, G. Hallmans and S. Rantapaa-Dahlqvist (2006).
"PTPN22 polymorphism and anti-cyclic citrullinated peptide antibodies in
combination strongly predicts future onset of rheumatoid arthritis and has a
specificity of 100% for the disease." Arthritis Res Ther 8(1): R19.
Karason, A., T. J. Love and B. Gudbjornsson (2009). "A strong heritability of
psoriatic arthritis over four generations--the Reykjavik Psoriatic Arthritis Study."
Rheumatology (Oxford) 48(11): 1424-1428.
69
Kastbom, A., L. Arlestig and S. Rantapaa-Dahlqvist (2015). "Genetic Variants of
the NLRP3 Inflammasome Are Associated with Stroke in Patients with
Rheumatoid Arthritis." J Rheumatol 42(10): 1740-1745.
Kastbom, A., M. Johansson, D. Verma, P. Soderkvist and S. Rantapaa-Dahlqvist
(2010). "CARD8 p.C10X polymorphism is associated with inflammatory activity
in early rheumatoid arthritis." Ann Rheum Dis 69(4): 723-726.
Kastbom, A., E. Klingberg, D. Verma, H. Carlsten, H. Forsblad-d'Elia, J.
Wesamaa, J. Cedergren, P. Eriksson and P. Soderkvist (2013). "Genetic variants
in CARD8 but not in NLRP3 are associated with ankylosing spondylitis." Scand J
Rheumatol 42(6): 465-468.
Kastbom, A., D. Verma, P. Eriksson, T. Skogh, G. Wingren and P. Soderkvist
(2008). "Genetic variation in proteins of the cryopyrin inflammasome influences
susceptibility and severity of rheumatoid arthritis (the Swedish TIRA project)."
Rheumatology (Oxford) 47(4): 415-417.
Kokkonen, H., M. Johansson, L. Innala, E. Jidell and S. Rantapaa-Dahlqvist
(2007). "The PTPN22 1858C/T polymorphism is associated with anti-cyclic
citrullinated peptide antibody-positive early rheumatoid arthritis in northern
Sweden." Arthritis Res Ther 9(3): R56.
Kyogoku, C., C. D. Langefeld, W. A. Ortmann, A. Lee, S. Selby, V. E. Carlton, M.
Chang, P. Ramos, E. C. Baechler, F. M. Batliwalla, J. Novitzke, A. H. Williams, C.
Gillett, P. Rodine, R. R. Graham, K. G. Ardlie, P. M. Gaffney, K. L. Moser, M. Petri,
A. B. Begovich, P. K. Gregersen and T. W. Behrens (2004). "Genetic association
of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with
human SLE." Am J Hum Genet 75(3): 504-507.
Leipe, J., M. Grunke, C. Dechant, C. Reindl, U. Kerzendorf, H. Schulze-Koops and
A. Skapenko (2010). "Role of Th17 cells in human autoimmune arthritis."
Arthritis Rheum 62(10): 2876-2885.
Libby, P., P. M. Ridker, G. K. Hansson and A. Leducq Transatlantic Network on
(2009). "Inflammation in atherosclerosis: from pathophysiology to practice." J
Am Coll Cardiol 54(23): 2129-2138.
Lindqvist, U., G. Kristjansson, I. Pihl-Lundin, E. Hagforsen and G. Michaelsson
(2006). "Patients with psoriatic arthritis have an increased number of
lymphocytes in the duodenal mucosa in comparison with patients with psoriasis
vulgaris." J Rheumatol 33(5): 924-927.
70
Liu, J. T., H. M. Yeh, S. Y. Liu and K. T. Chen (2014). "Psoriatic arthritis:
Epidemiology, diagnosis, and treatment." World J Orthop 5(4): 537-543.
Liu, Y., C. Helms, W. Liao, L. C. Zaba, S. Duan, J. Gardner, C. Wise, A. Miner, M.
J. Malloy, C. R. Pullinger, J. P. Kane, S. Saccone, J. Worthington, I. Bruce, P. Y.
Kwok, A. Menter, J. Krueger, A. Barton, N. L. Saccone and A. M. Bowcock (2008).
"A genome-wide association study of psoriasis and psoriatic arthritis identifies
new disease loci." PLoS Genet 4(3): e1000041.
Loft, N. D., L. Skov, M. K. Rasmussen, R. Gniadecki, T. N. Dam, I. Brandslund,
H. J. Hoffmann, M. R. Andersen, R. B. Dessau, A. C. Bergmann, N. M. Andersen,
M. K. Abildtoft, P. S. Andersen, M. L. Hetland, B. Glintborg, S. Bank, U. Vogel
and V. Andersen (2018). "Genetic polymorphisms associated with psoriasis and
development of psoriatic arthritis in patients with psoriasis." PLoS One 13(2):
e0192010.
Lowes, M. A., M. Suarez-Farinas and J. G. Krueger (2014). "Immunology of
psoriasis." Annu Rev Immunol 32: 227-255.
Madland, T. M., A. Larsen and J. G. Brun (2007). "S100 proteins calprotectin and
S100A12 are related to radiographic changes rather than disease activity in
psoriatic arthritis with low disease activity." J Rheumatol 34(10): 2089-2092.
Marchesoni, A., G. De Marco, M. Merashli, F. McKenna, I. Tinazzi, H. Marzo-
Ortega and D. G. McGonagle (2018). "The problem in differentiation between
psoriatic-related polyenthesitis and fibromyalgia." Rheumatology (Oxford) 57(1):
32-40.
Mc Ardle, A., B. Flatley, S. R. Pennington and O. FitzGerald (2015). "Early
biomarkers of joint damage in rheumatoid and psoriatic arthritis." Arthritis Res
Ther 17: 141.
McGonagle, D., W. Gibbon and P. Emery (1998). "Classification of inflammatory
arthritis by enthesitis." Lancet 352(9134): 1137-1140.
McGonagle, D. and M. F. McDermott (2006). "A proposed classification of the
immunological diseases." PLoS Med 3(8): e297.
Mease, P. J. (2011). "Inflammatory musculoskeletal disease: identification and
assessment." J Rheumatol 38(3): 557-561.
Mease, P. J., C. Karki, J. B. Palmer, C. J. Etzel, A. Kavanaugh, C. T. Ritchlin, W.
Malley, V. Herrera, M. Tran and J. D. Greenberg (2017). "Clinical Characteristics,
71
Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients
With Dactylitis or Enthesitis: Results From the Corrona Psoriatic
Arthritis/Spondyloarthritis Registry." Arthritis Care Res (Hoboken) 69(11):
1692-1699.
Menon, B., N. J. Gullick, G. J. Walter, M. Rajasekhar, T. Garrood, H. G. Evans, L.
S. Taams and B. W. Kirkham (2014). "Interleukin-17+CD8+ T cells are enriched
in the joints of patients with psoriatic arthritis and correlate with disease activity
and joint damage progression." Arthritis Rheumatol 66(5): 1272-1281.
Miller, I. M., C. Ellervik, S. Yazdanyar and G. B. Jemec (2013). "Meta-analysis of
psoriasis, cardiovascular disease, and associated risk factors." J Am Acad
Dermatol 69(6): 1014-1024.
Moll, J. M. and V. Wright (1973). "Psoriatic arthritis." Semin Arthritis Rheum
3(1): 55-78.
Mosmann, T. R. and R. L. Coffman (1989). "TH1 and TH2 cells: different patterns
of lymphokine secretion lead to different functional properties." Annu Rev
Immunol 7: 145-173.
Ogdie, A., K. Haynes, A. B. Troxel, T. J. Love, S. Hennessy, H. Choi and J. M.
Gelfand (2014). "Risk of mortality in patients with psoriatic arthritis, rheumatoid
arthritis and psoriasis: a longitudinal cohort study." Ann Rheum Dis 73(1): 149-
153.
Ogdie, A., S. Maliha, D. Shin, T. J. Love, J. Baker, Y. Jiang, H. Choi and J. M.
Gelfand (2017). "Cause-specific mortality in patients with psoriatic arthritis and
rheumatoid arthritis." Rheumatology (Oxford) 56(6): 907-911.
Orbai, A. M., M. de Wit, P. Mease, J. A. Shea, L. Gossec, Y. Y. Leung, W. Tillett,
M. Elmamoun, K. Callis Duffin, W. Campbell, R. Christensen, L. Coates, E. Dures,
L. Eder, O. FitzGerald, D. Gladman, N. Goel, S. D. Grieb, S. Hewlett, P. Hoejgaard,
U. Kalyoncu, C. Lindsay, N. McHugh, B. Shea, I. Steinkoenig, V. Strand and A.
Ogdie (2017). "International patient and physician consensus on a psoriatic
arthritis core outcome set for clinical trials." Ann Rheum Dis 76(4): 673-680.
Ostergaard, M., L. Eder, S. N. Christiansen and G. S. Kaeley (2016). "Imaging in
the diagnosis and management of peripheral psoriatic arthritis-The clinical utility
of magnetic resonance imaging and ultrasonography." Best Pract Res Clin
Rheumatol 30(4): 624-637.
72
Paramel, G. V., A. Sirsjo and K. Fransen (2015). "Role of genetic alterations in the
NLRP3 and CARD8 genes in health and disease." Mediators Inflamm 2015:
846782.
Pattison, E., B. J. Harrison, C. E. Griffiths, A. J. Silman and I. N. Bruce (2008).
"Environmental risk factors for the development of psoriatic arthritis: results
from a case-control study." Ann Rheum Dis 67(5): 672-676.
Peluso, R., S. Iervolino, M. Vitiello, V. Bruner, G. Lupoli and M. N. Di Minno
(2015). "Extra-articular manifestations in psoriatic arthritis patients." Clin
Rheumatol 34(4): 745-753.
Peters, M. J., D. P. Symmons, D. McCarey, B. A. Dijkmans, P. Nicola, T. K. Kvien,
I. B. McInnes, H. Haentzschel, M. A. Gonzalez-Gay, S. Provan, A. Semb, P.
Sidiropoulos, G. Kitas, Y. M. Smulders, M. Soubrier, Z. Szekanecz, N. Sattar and
M. T. Nurmohamed (2010). "EULAR evidence-based recommendations for
cardiovascular risk management in patients with rheumatoid arthritis and other
forms of inflammatory arthritis." Ann Rheum Dis 69(2): 325-331.
Polachek, A., S. Li, V. Chandran and D. D. Gladman (2017). "Clinical Enthesitis
in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence,
Characteristics, and Outcome." Arthritis Care Res (Hoboken) 69(11): 1685-1691.
Polachek, A., Z. Touma, M. Anderson and L. Eder (2017). "Risk of Cardiovascular
Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational
Studies." Arthritis Care Res (Hoboken) 69(1): 67-74.
Przepiera-Bedzak, H., K. Fischer and M. Brzosko (2016). "Extra-Articular
Symptoms in Constellation with Selected Serum Cytokines and Disease Activity
in Spondyloarthritis." Mediators Inflamm 2016: 7617954.
Przepiera-Bedzak, H., K. Fischer and M. Brzosko (2016). "Serum Interleukin-18,
Fetuin-A, Soluble Intercellular Adhesion Molecule-1, and Endothelin-1 in
Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome." Int J Mol Sci
17(8).
Ramonda, R., V. Modesti, A. Ortolan, A. Scanu, N. Bassi, F. Oliviero and L. Punzi
(2013). "Serological markers in psoriatic arthritis: promising tools." Exp Biol Med
(Maywood) 238(12): 1431-1436.
Reece, R. J., J. D. Canete, W. J. Parsons, P. Emery and D. J. Veale (1999).
"Distinct vascular patterns of early synovitis in psoriatic, reactive, and
rheumatoid arthritis." Arthritis Rheum 42(7): 1481-1484.
73
Rhee, I. and A. Veillette (2012). "Protein tyrosine phosphatases in lymphocyte
activation and autoimmunity." Nat Immunol 13(5): 439-447.
Rifbjerg-Madsen, S., A. W. Christensen, R. Christensen, M. L. Hetland, H.
Bliddal, L. E. Kristensen, B. Danneskiold-Samsoe and K. Amris (2017). "Pain and
pain mechanisms in patients with inflammatory arthritis: A Danish nationwide
cross-sectional DANBIO registry survey." PLoS One 12(7): e0180014.
Roberts, R. L., R. K. Topless, A. J. Phipps-Green, R. B. Gearry, M. L. Barclay and
T. R. Merriman (2010). "Evidence of interaction of CARD8 rs2043211 with
NALP3 rs35829419 in Crohn's disease." Genes Immun 11(4): 351-356.
Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh and M. Toda (1995).
"Immunologic self-tolerance maintained by activated T cells expressing IL-2
receptor alpha-chains (CD25). Breakdown of a single mechanism of self-
tolerance causes various autoimmune diseases." J Immunol 155(3): 1151-1164.
Sakkas, L. I., I. Alexiou, T. Simopoulou and M. Vlychou (2013). "Enthesitis in
psoriatic arthritis." Semin Arthritis Rheum 43(3): 325-334.
Scarpa, R., F. Manguso, A. D'Arienzo, F. P. D'Armiento, C. Astarita, G. Mazzacca
and F. Ayala (2000). "Microscopic inflammatory changes in colon of patients
with both active psoriasis and psoriatic arthritis without bowel symptoms." J
Rheumatol 27(5): 1241-1246.
Scarpa, R., P. Oriente, A. Pucino, M. Torella, L. Vignone, A. Riccio and C. Biondi
Oriente (1984). "Psoriatic arthritis in psoriatic patients." Br J Rheumatol 23(4):
246-250.
Schaible, H. G., G. S. von Banchet, M. K. Boettger, R. Brauer, M. Gajda, F. Richter,
S. Hensellek, D. Brenn and G. Natura (2010). "The role of proinflammatory
cytokines in the generation and maintenance of joint pain." Ann N Y Acad Sci
1193: 60-69.
Schatteman, L., H. Mielants, E. M. Veys, C. Cuvelier, M. De Vos, L. Gyselbrecht,
D. Elewaut and S. Goemaere (1995). "Gut inflammation in psoriatic arthritis: a
prospective ileocolonoscopic study." J Rheumatol 22(4): 680-683.
Schoultz, I., D. Verma, J. Halfvarsson, L. Torkvist, M. Fredrikson, U. Sjoqvist, M.
Lordal, C. Tysk, M. Lerm, P. Soderkvist and J. D. Soderholm (2009). "Combined
polymorphisms in genes encoding the inflammasome components NALP3 and
CARD8 confer susceptibility to Crohn's disease in Swedish men." Am J
Gastroenterol 104(5): 1180-1188.
74
Setty, A. R. and H. K. Choi (2007). "Psoriatic arthritis epidemiology." Curr
Rheumatol Rep 9(6): 449-454.
Shbeeb, M., K. M. Uramoto, L. E. Gibson, W. M. O'Fallon and S. E. Gabriel
(2000). "The epidemiology of psoriatic arthritis in Olmsted County, Minnesota,
USA, 1982-1991." J Rheumatol 27(5): 1247-1250.
Soare, A., S. Weber, L. Maul, S. Rauber, A. M. Gheorghiu, M. Luber, I. Houssni,
A. Kleyer, G. von Pickardt, M. Gado, D. Simon, J. Rech, G. Schett, J. H. W. Distler
and A. Ramming (2018). "Cutting Edge: Homeostasis of Innate Lymphoid Cells
Is Imbalanced in Psoriatic Arthritis." J Immunol 200(4): 1249-1254.
Sokoll, K. B. and P. S. Helliwell (2001). "Comparison of disability and quality of
life in rheumatoid and psoriatic arthritis." J Rheumatol 28(8): 1842-1846.
Spadaro, A., E. Taccari, V. Riccieri, F. Sensi, A. Sili Scavalli and A. Zoppini (1996).
"Interleukin-6 and soluble interleukin-2-receptor in psoriatic arthritis:
correlations with clinical and laboratory parameters." Clin Exp Rheumatol 14(4):
413-416.
Spalinger, M. R., S. Kasper, C. Gottier, S. Lang, K. Atrott, S. R. Vavricka, S. Scharl,
P. M. Gutte, M. G. Grutter, H. D. Beer, E. Contassot, A. C. Chan, X. Dai, D. J.
Rawlings, F. Mair, B. Becher, W. Falk, M. Fried, G. Rogler and M. Scharl (2016).
"NLRP3 tyrosine phosphorylation is controlled by protein tyrosine phosphatase
PTPN22." J Clin Invest 126(5): 1783-1800.
Spalinger, M. R., S. Lang, C. Gottier, X. Dai, D. J. Rawlings, A. C. Chan, G. Rogler
and M. Scharl (2017). "PTPN22 regulates NLRP3-mediated IL1B secretion in an
autophagy-dependent manner." Autophagy 13(9): 1590-1601.
Stanford, S. M. and N. Bottini (2014). "PTPN22: the archetypal non-HLA
autoimmunity gene." Nat Rev Rheumatol 10(10): 602-611.
Strowig, T., J. Henao-Mejia, E. Elinav and R. Flavell (2012). "Inflammasomes in
health and disease." Nature 481(7381): 278-286.
Stuart, P. E., R. P. Nair, L. C. Tsoi, T. Tejasvi, S. Das, H. M. Kang, E. Ellinghaus,
V. Chandran, K. Callis-Duffin, R. Ike, Y. Li, X. Wen, C. Enerback, J. E.
Gudjonsson, S. Koks, K. Kingo, T. Esko, U. Mrowietz, A. Reis, H. E. Wichmann,
C. Gieger, P. Hoffmann, M. M. Nothen, J. Winkelmann, M. Kunz, E. G. Moreta,
P. J. Mease, C. T. Ritchlin, A. M. Bowcock, G. G. Krueger, H. W. Lim, S.
Weidinger, M. Weichenthal, J. J. Voorhees, P. Rahman, P. K. Gregersen, A.
Franke, D. D. Gladman, G. R. Abecasis and J. T. Elder (2015). "Genome-wide
75
Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals
Differences in Their Genetic Architecture." Am J Hum Genet 97(6): 816-836.
Szodoray, P., P. Alex, C. M. Chappell-Woodward, T. M. Madland, N. Knowlton, I.
Dozmorov, M. Zeher, J. N. Jarvis, B. Nakken, J. G. Brun and M. Centola (2007).
"Circulating cytokines in Norwegian patients with psoriatic arthritis determined
by a multiplex cytokine array system." Rheumatology (Oxford) 46(3): 417-425.
Takeshita, J., S. Grewal, S. M. Langan, N. N. Mehta, A. Ogdie, A. S. Van Voorhees
and J. M. Gelfand (2017). "Psoriasis and comorbid diseases: Epidemiology." J Am
Acad Dermatol 76(3): 377-390.
Taylor, W., D. Gladman, P. Helliwell, A. Marchesoni, P. Mease, H. Mielants and
C. S. Group (2006). "Classification criteria for psoriatic arthritis: development of
new criteria from a large international study." Arthritis Rheum 54(8): 2665-
2673.
Theander, E., T. Husmark, G. M. Alenius, P. T. Larsson, A. Teleman, M. Geijer
and U. R. Lindqvist (2014). "Early psoriatic arthritis: short symptom duration,
male gender and preserved physical functioning at presentation predict
favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic
Arthritis Register (SwePsA)." Ann Rheum Dis 73(2): 407-413.
Tillett, W., D. Jadon, G. Shaddick, C. Cavill, E. Korendowych, C. S. de Vries and
N. McHugh (2013). "Smoking and delay to diagnosis are associated with poorer
functional outcome in psoriatic arthritis." Ann Rheum Dis 72(8): 1358-1361.
Tobin, A. M., D. J. Veale, O. Fitzgerald, S. Rogers, P. Collins, D. O'Shea and B.
Kirby (2010). "Cardiovascular disease and risk factors in patients with psoriasis
and psoriatic arthritis." J Rheumatol 37(7): 1386-1394.
Trygg, J. and S. Wold (2002). "Orthogonal projections to latent structures (O-
PLS)." Journal of Chemometrics 16(3): 119-128.
Wallberg-Jonsson, S., H. Johansson, M. L. Ohman and S. Rantapaa-Dahlqvist
(1999). "Extent of inflammation predicts cardiovascular disease and overall
mortality in seropositive rheumatoid arthritis. A retrospective cohort study from
disease onset." J Rheumatol 26(12): 2562-2571.
Wallberg-Jonsson, S., M. L. Ohman and S. R. Dahlqvist (1997). "Cardiovascular
morbidity and mortality in patients with seropositive rheumatoid arthritis in
Northern Sweden." J Rheumatol 24(3): 445-451.
76
van Kuijk, A. W., P. Reinders-Blankert, T. J. Smeets, B. A. Dijkmans and P. P. Tak
(2006). "Detailed analysis of the cell infiltrate and the expression of mediators of
synovial inflammation and joint destruction in the synovium of patients with
psoriatic arthritis: implications for treatment." Ann Rheum Dis 65(12): 1551-
1557.
Vang, T., M. Congia, M. D. Macis, L. Musumeci, V. Orru, P. Zavattari, K. Nika, L.
Tautz, K. Tasken, F. Cucca, T. Mustelin and N. Bottini (2005). "Autoimmune-
associated lymphoid tyrosine phosphatase is a gain-of-function variant." Nat
Genet 37(12): 1317-1319.
Wang, Y., I. Shaked, S. M. Stanford, W. Zhou, J. M. Curtsinger, Z. Mikulski, Z. R.
Shaheen, G. Cheng, K. Sawatzke, A. M. Campbell, J. L. Auger, H. Bilgic, F. M.
Shoyama, D. O. Schmeling, H. H. Balfour, Jr., K. Hasegawa, A. C. Chan, J. A.
Corbett, B. A. Binstadt, M. F. Mescher, K. Ley, N. Bottini and E. J. Peterson
(2013). "The autoimmunity-associated gene PTPN22 potentiates toll-like
receptor-driven, type 1 interferon-dependent immunity." Immunity 39(1): 111-
122.
Verma, D., M. Lerm, R. Blomgran Julinder, P. Eriksson, P. Soderkvist and E.
Sarndahl (2008). "Gene polymorphisms in the NALP3 inflammasome are
associated with interleukin-1 production and severe inflammation: relation to
common inflammatory diseases?" Arthritis Rheum 58(3): 888-894.
Verma, D., E. Sarndahl, H. Andersson, P. Eriksson, M. Fredrikson, J. I. Jonsson,
M. Lerm and P. Soderkvist (2012). "The Q705K polymorphism in NLRP3 is a
gain-of-function alteration leading to excessive interleukin-1beta and IL-18
production." PLoS One 7(4): e34977.
Villanova, F., P. Di Meglio and F. O. Nestle (2013). "Biomarkers in psoriasis and
psoriatic arthritis." Ann Rheum Dis 72 Suppl 2: ii104-110.
Wilson, F. C., M. Icen, C. S. Crowson, M. T. McEvoy, S. E. Gabriel and H. M.
Kremers (2009). "Incidence and clinical predictors of psoriatic arthritis in
patients with psoriasis: a population-based study." Arthritis Rheum 61(2): 233-
239.
Wilson, P. W., R. B. D'Agostino, D. Levy, A. M. Belanger, H. Silbershatz and W.
B. Kannel (1998). "Prediction of coronary heart disease using risk factor
categories." Circulation 97(18): 1837-1847.
Wilson, S. P. and S. L. Cassel (2010). "Inflammasome-mediated
autoinflammatory disorders." Postgrad Med 122(5): 125-133.
77
Wong, K., D. D. Gladman, J. Husted, J. A. Long and V. T. Farewell (1997).
"Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I.
Causes and risk of death." Arthritis Rheum 40(10): 1868-1872.
Woolf, C. J. (2011). "Central sensitization: implications for the diagnosis and
treatment of pain." Pain 152(3 Suppl): S2-15.
Xiong, T. and J. E. Turner (2018). "Innate lymphoid cells in autoimmunity and
chronic inflammatory diseases." Semin Immunopathol.
Yusuf, S., S. Reddy, S. Ounpuu and S. Anand (2001). "Global burden of
cardiovascular diseases: part I: general considerations, the epidemiologic
transition, risk factors, and impact of urbanization." Circulation 104(22): 2746-
2753.